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The concentration of protein biomarkers in the bloodstream can be an effective 
indicator of disease processes. Rapid, simple, portable and inexpensive diagnostic 
devices can improve healthcare by increasing access to protein-based diagnostic 
technologies, shifting them from centralized laboratories to decentralized point-of-care 
locations. This dissertation describes the development of two signal transductions 
methods, Label-Acquired Magnetorotation (LAM), and its successor, Bead Assembly 
Magnetorotation (BAM) as a magnetic bead-based signal transduction mechanism for 
decentralized protein diagnostic applications. LAM and BAM use the concentration of 
the target protein to mediate the formation of a magnetic bead assembly. LAM is 
performed by taking 1 μm magnetic beads and 10 μm nonmagnetic spheres, 
functionalizing them with affinity molecules against the target protein, mixing them with 
a solution containing the protein, and then allowing the protein to mediate the attachment 
of the 1 μm magnetic beads to the 10 μm nonmagnetic spheres. In an asynchronously 
rotating magnetic field, the rotational frequency of the nonmagnetic sphere depends on 
the number of attached magnetic beads, which depends on the concentration of the 
protein. BAM is performed by taking the same functionalized 1 μm magnetic beads, 
mixing them with a solution containing the protein, and then plating 1 μL inverted 
droplets of the solution on a Teflon-coated slide. As the beads fall through the solution to 
the bottom of the droplet, the protein mediates the formation of the beads into an 
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assembly. In the case of high protein concentration, the beads form a loosely-packed 
assembly. In the case of no or low protein concentration, and the beads form a tightly-
packed assembly. In an asynchronously rotating magnetic field, the rotational period of 
the assembly will depend on its packing density, which depends on the concentration of 
the protein. This thesis discusses the development of LAM and BAM, where BAM yields 
one of the lowest limits of detection ever reported for the protein thrombin. Additionally, 
it discusses the development of a portable laser-and-photodiode diagnostic platform 
prototype, as well as attempts to translate BAM into serum. A separate project shows the 






 The concentration of certain key proteins in the bloodstream can yield insight into 
disease and other physiological processes. [1, 2] The goal of a protein diagnostic system 
is to rapidly and accurately measure the concentration of these proteins. Reducing the 
size, cost, analysis time, and the complexity of these diagnostic systems could increase 
the accessibility of these technologies to greater segments of the population, by moving 
them from centralized laboratories to decentralized point-of-care locations. [3, 4] There 
are three primary components in a protein diagnostic system: the target protein that the 
system is attempting to detect, the affinity molecules used to capture the target, and the 
signal transduction mechanism by which a successful binding event is transduced into a 
signal that can be quantified and recorded by the user. The focus of this thesis is on the 
third part of these systems, the signal transduction mechanism.  
 There are a wide variety of signal transduction mechanisms currently in use, 
including fluorescent probes, [5-10] electrochemistry, [11-18] surface plasmon resonance 
(SPR), [19-22] and a number of magnetic-based methods, including giant 
magnetoresistance (GMR), [23-27], magnetic relaxation (MR), [28-31] and Hall probes. 
[32-34]  
The primary challenge associated with using fluorescent probes as signal 
transducers is the cost of the detection apparatus, [35] and the primary challenge 
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associated with using electrochemistry as the signal transducer is false positives, due to 
electrolytes and nonspecific signals generated by proteins and other molecules found in 
biological fluids. [36] Of the magnetic signal transduction systems, none are currently in 
clinical use; all remain in the stage of laboratory development.  
This dissertation focuses on the development of a novel protein diagnostic signal 
transduction mechanism based on the asynchronous magnetic rotation of magnetic beads, 
using aptamers as affinity molecules, as well as on a project demonstrating the use of 
aptamers as affinity reagents in an integrated electrophoretic lab-on-a-chip platform. This 
introductory chapter discusses affinity molecules, other key protein diagnostic systems 




 Affinity molecules are molecules that bind with high specificity and selectivity to 
a molecular target, such as a protein or other small biomolecule. [2] The most common 
type of affinity molecule is an antibody, which is a protein that binds to its molecular 
target. Antibodies for research applications are produced by injecting an animal such as a 
mouse, goat, sheep, or rabbit with the molecular target, which will cause the animal to 
produce the antibodies through its own immune system. The antibodies are then 
harvested from the animal’s blood stream (polyclonal antibodies) or from lymphocytes 
which are isolated from the animal and cloned in vitro (monoclonal antibodies). [37, 38] 
Antibodies have in their structure a target-specific variable region, which binds to the 
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target by non-covalent interactions between the antibody’s variable region and the 
epitope region on the target molecule. 
 Aptamers, unlike amino acids, are synthetically-generated affinity molecules that 
are composed of single- or double-stranded nucleic acid sequences, typically on the order 
of 15-100 base pairs. [39, 40] Like antibodies, aptamers bind to the epitope region of 
their target protein via non-covalent interactions between a part of the aptamer and the 
epitope. Most aptamers are derived through the SELEX (systematic evolution of ligands 
by exponential enrichment) process, where a randomly generated pool of 
oligonucleotides is mixed with the molecular target and oligonucleotides that display 
affinity for the target are separated and amplified repeatedly until the highest affinity 
oligonucleotides are isolated. [39, 41] Aptamers have several advantages over antibodies 
for diagnostic applications. Because they are synthetic, aptamers can be developed 
against any molecular target, without needing to use any animals. Once an aptamer 
sequence is identified, additional copies of the aptamer can be produced for 
approximately 100-1000 times lower cost than antibodies. Aptamers are also significantly 
more robust than antibodies, maintaining stability at room temperature for periods of 
weeks or even months. [42] 
 Two of the most popular aptamers are the thrombin aptamers, the first of which, 
the 15-mer, was discovered in 1992, [43] and the second of which, the 29-mer, was 
discovered in 1997. [44] The aptamers bind to the fibrin exosite (15-mer) and heparin 
exosite (29-mer) of the thrombin protein, which is a blood protein that is a component in 
the fibrin coagulation cascade. These aptamers were originally thought to have 
therapeutic application as anti-clotting agents. [43-45] However, when that therapeutic 
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potential failed to materialize, [46] the aptamers took on a second life as a sandwich pair 
of affinity molecules for diagnostic device development.  
 A sandwich pair is a pair of affinity molecules that bind to opposite sides of a 
protein target. Having a sandwich pair of affinity molecules (as opposed to using only a 
single affinity molecule) allows for two-step diagnostic systems: the first is the capture 
step, where the target is captured by a larger substrate; and the second is the detection 
step, where a label binds to the captured protein, allowing for the transduction of a signal. 
The advantage of this two-step method is the increased specificity of the system, reducing 
the rate of false positives. [47] Given that the thrombin aptamers were the only sandwich 
pair of aptamers available, and the numerous advantages of using aptamers listed above, 
the thrombin aptamers have become a very popular choice for demonstrating proof-of-
principle of new diagnostic systems. [15-18, 48-61] For these same reasons the thrombin 
aptamers are the focus of most of the work in this dissertation. An added benefit of this 
choice is that it makes it easier to benchmark the work here against the work of others. 
 Another important set of affinity molecules are streptavidin and biotin. 
Streptavidin is a tetrameric protein (MW ~ 60 kDa) isolated from the bacteria 
Streptomyces avidinii, and biotin is a small molecule (MW ~ 244 Da), also known as 
Vitamin B7. [62] Streptavidin and biotin form the strongest non-covalent bond found in 
nature, with a dissociation constant on the order of 10-15 M. [63] Streptavidin and biotin 
have two primary uses within diagnostic systems: one is to serve as an affinity molecule 
system for very early stage system development, and the other is to facilitate conjugation 





 The gold standard in diagnostic assays is ELISA, the Enzyme Linked 
Immunosorbent Assay. Invented in the 1960s, ELISA has become the most popular 
method for performing diagnostic assays. The fundamental principle behind ELISA is to 
use the presence (or absence) of an enzymatic label, which binds to the target via an 
affinity molecule, to induce a colorimetric change in proportion to the concentration of 
the target protein. [64] There are several different types of ELISA assays that can be 
performed. Some of the more popular types are the indirect, direct and sandwich ELISA.  
 An indirect ELISA assay tests for the presence of antibodies against a specific 
antigen, rather than for the presence of the antigen itself. In an indirect ELISA, the 
antigen of interest is immobilized to the surface of a plate, after which a solution 
containing the target antibody is added to the plate. The target antibody binds to the 
antigen immobilized on the surface of the plate. The plate is washed to remove any 
unbound antibodies, and the enzyme-labeled secondary antibody is introduced. If the 
primary antibody was present in the original solution, then the enzymatically-labeled 
secondary antibody will bind to it, causing the desired color change to occur in the 
solution. If the primary antibody was not present, then the enzymatically-labeled 
secondary antibody will not remain in the solution, and the color change will not occur. If 
the test requires only a qualitative detection of color change (e.g. low, medium or high 
intensity), then visual observation is usually sufficient to yield an answer. If a 
quantitative result is required, then a plate reader is typically used to measure the 
intensity of the color signal in the solution. A direct ELISA is similar to an indirect 
ELISA, except the primary antibody is labeled with the enzyme, so that the secondary 
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antibody is not needed. Using two antibodies in an ELISA rather than just one typically 
result in greater specificity and lower rates of false positives. 
 A sandwich assay can be performed to detect either an antigen or an antibody, 
although it is most frequently used for antigen detection. The sandwich assay requires 
two antibodies against the target antigen, a capture antibody and a detection antibody. 
The capture antibody is immobilized to the surface of a plate. A solution containing the 
target antigen is added, allowed to incubate for a specified period of time, and then 
washed to remove any unbound antigen. The detection antibody is then introduced, which 
binds to any antigens that were captured in the first step. A washing step then removes 
any unbound detection antibody. Finally, an enzymatically-labeled secondary antibody is 
introduced, which binds specifically to any detection antibodies that are present. A 
washing step then removes any unbound secondary antibody. After the enzymes are 
allowed to react for a specified amount of time, the plate can be analyzed to determine 
the concentration of antigen that was present. Typically, a greater concentration of 
antigen will result in a greater color change.  
 Unlike ELISA-based sensors, which use a colorimetric or fluorescent change as 
the signal transduction mechanism, electrochemical sensors use changes in current as the 
signal transduction mechanism. [13] Electrochemical sensors are similar to ELISA-based 
sensors in that the target analyte is captured by an affinity molecule(s), but instead of 
being conjugated to an enzyme or molecule that produces a chromometric change, they 
are conjugated to an enzyme or molecule that produces an electrochemical change. There 
are several different classes of electrochemical sensors: amperometric, potentiometric, 
and impedimetric. Amperometric sensors use the product of a reduction or oxidation 
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reaction to generate the signal-transducing current. [11, 12] Potentiometric sensors use 
ion-selective electrodes to generate their signal-transducing currents. [14, 15] 
Impedimetric sensors use the binding of the target and associated labeling molecules to 
cause a change in the impedance of a conductor. [16, 17, 36] ELISA- and 
electrochemical-based biosensors are probably the two most popular classes of biosensor 
signal transduction methods.  
 Another class of biodetectors is capillary electrophoresis. In capillary 
electrophoresis, molecules are separated through a viscous medium (a gel or a fluid) by 
an electric field on the basis of differences in their charge-to-mass ratio. [65, 66] The 
target molecule is captured by a fluorescently-tagged affinity molecule, at which point 
two classes of fluorescent compounds exist in the solution: target-fluorophore complexes, 
and free fluorophore. These two compounds are separated in the electrophoretic gel on 
the basis of their different migration times, and are detected by a fluorescent detector at 
the end of the capillary. The capillaries used are typically microfluidic, which enables 
them to be miniaturized for point-of-care detection. [5, 41, 67] 
 There are several signal transduction methods that make use of magnetic particles, 
including giant magnetoresistance (GMR) and magnetic relaxation (MR). GMR is similar 
in concept to impedimetric electrochemical sensing. The surface of an electromagnetic 
sensor is functionalized with capture affinity molecules for the target. After the target is 
captured, detection affinity molecules functionalized with magnetic particles are 
introduced, and sandwich the target. The proximity of the particles to the sensor surface 
changes the resistivity of the sensor, which can be detected by passing a constant current 
through the sensor and measuring the change in the voltage across the sensor. [24, 68] 
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The most successful example of GMR is probably the work of Shan Wang. Using 50 nm 
magnetic nanoparticles with a sensor size of 100 μm, his group was able to detect the 
biomarkers TNF-α (tumor necrosis factor alpha), hCG (human chorionic gonadotropin), 
CEA (carcinoembryonic antigen), and IFN-γ (interferon gamma) at levels ranging from 
femtomolar in buffer to low picomolar in serum. [23] 
 Magnetic Relaxation is perhaps the method most similar to the work presented in 
this thesis. The MR detection method is based on functionalizing magnetic nanoparticles 
with affinity molecules against the target, and mixing them with a solution containing the 
target. The target will mediate the binding of the particles to each other to form clusters, 
with larger clusters corresponding to greater concentrations of protein. The signal is 
transduced by applying a strong, high-frequency magnetic field to the solution containing 
the particles, and measuring the relaxation time of the particles, which will depend on the 
size of the clusters that they form. [25, 30] The most successful example of MR is the 
work of Ralph Weissleder. The Weissleder group built an MR detection system using 
both 38 nm magnetic particles and 1 μm magnetic beads, and generated a 0.5 T, 21 MHz 
excitation field using a 1.25 kg permanent magnet, with microfabricated microcoils as the 
detection sensors. [28] The system was able to detect IgG in buffer below 1 pM, [69] and 
VEGF (vascular endothelial growth factor) in serum at 4.7 pM. [70] 
 
Magnetism 
There are three types of magnetic materials: ferromagnetic, paramagnetic, and 
diamagnetic. Ferromagnetic materials, such as iron, have a permanent magnetic moment 
that exists even in the absence of an external magnetic field. Paramagnetic materials do 
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not have a permanent magnetic moment, and exhibit a weak magnetic attraction only in 
the presence of an external magnetic field. Diamagnetic materials also do not have a 
permanent magnetic moment, and exhibit a weak magnetic repulsion only in the presence 
of an external magnetic field. [71] There is a special class of magnetic materials, called 
superparamagnetic, that is a combination of ferromagnetism and paramagnetism. A 
ferromagnetic material is composed of many small magnetic domains (typically on the 
order of tens of nanometers) that maintain their magnetic moment based on nearest-
neighbor interactions. However, if a ferromagnetic material is broken up into very small 
segments, below the single domain size (~ 30 nm), then the domain no longer has any 
neighbors, and therefore it cannot maintain a permanent magnetic moment. In the 
presence of an external magnetic field, the domain will reassume the strong magnetic 
attraction (much stronger than typical paramagnetic attractions) associated with its 
multidomain version. Such materials are called superparamagnetic materials. [72] 
Superparamagnetic beads (micron-sized polystyrene beads with embedded 8-nm 
superparamagnetic iron oxide particles) are very useful for biological applications 
because they have no net magnetic moment, which allows for them to mix well in 
solution without clumping, and then when a field is applied, exhibit strong magnetization. 
The rotation of a superparamagnetic bead in a rotating magnetic field can take 
place in two regimes: the synchronous regime, and the asynchronous regime. In the 
synchronous regime, the bead is phase locked with the field, and so rotates with the same 
period as the field. As the frequency of the field is increased beyond a critical frequency, 
the viscous drag forces opposing the rotation of the bead increase, such that the bead can 
no longer keep up with the rotation of the field, and it enters the asynchronous regime, 
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rotating with a non-constant phase lag relative to the field. [73, 74] The synchronous 
regime is less useful for making measurements, because the rate at which the bead rotates 
is fixed relative to that of the driving field. The asynchronous regime, however, is very 
useful for making measurements, because the rotational period of the bead depends on 
several parameters, including the volume, shape, and magnetic content of the bead. In 
this thesis we use the asynchronous magnetic rotation of superparamagnetic beads as 
signal transducers for measuring protein concentration. 
Significant work in the theory of asynchronous magnetic rotation was done by 
Connolly and St. Pierre, [75] Fannin et. al, [76] and Janssen et. al, [77] and much of the 
theoretical foundation of the work in this thesis was built upon their ideas. To describe 
the behavior of the beads, we start with the equation for magnetic torque, = ×τ m B , 
where m is the magnetic moment of the bead, and B is the strength of the external 
magnetic field. Assuming steady state rotation, the rotational driving forces are equal in 
magnitude and opposite in direction to the viscous drag forces. Setting up a torque 
balance, the drag term can be expanded, τ /HV Tκη= , where κ is the shape factor, η is 
the fluid viscosity, VH is the hydrodynamic volume, and T is the rotational period. The 
rotational driving forces can be expanded with the following substitutions, 0µ=B H , 
where μ0 is the permeability of free space, H is the magnetizing field; mV=m M , where 
Vm is the volume of magnetic material, and M is the volumetric magnetic moment; 
χ=M H , where χ is the magnetic susceptibility of the bead; and ' ''iχ χ χ= − , where χ’ 
is the real component of the bead susceptibility, and χ’’ is the imaginary component of 
the bead susceptibility. We can combine all of these expressions to create an equation for 
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This equation can be expressed in terms of experimentally measurable parameters by 
making further substitutions: ( ) ( )2 20'' / 1N Nχ χ τ τ= Ω +Ω , where χ0 is the DC bead 
susceptibility, Ω is the frequency of the driving field, and τN is the Neel relaxation time; 
( ) ( ){ }exp /N p B KKV k Tτ = , where K is the magnetic anisotropy constant, Vp is the volume 
of the magnetic nanoparticles, kB is Boltzmann’s constant and TK is the ambient 
temperature. These expressions can be combined to produce a single equation that 































The asynchronous rotation of magnetic beads has been used for a variety of other 
sensing applications, including measuring solution viscosity, [74] pH, [78] the growth of 
single bacteria, [73, 79-83] and cancer cells. [84] Additional examples include measuring 
the binding of bacteriophage by Brownian relaxation of magnetic beads, [29, 31, 85, 86] 
the rotation of analyte-linked magnetic particle chains, [87-90]  and fluorescently-labeled 







This thesis will discuss the development of the rotation of magnetic bead 
assemblies as a signal transduction mechanism for the detection of proteins. It will trace 
its development from inception, through two different generations, (1) the sandwich 
complex and (2) the bead assembly, with both biotin and thrombin as the detection 
targets; the development of a laser-and-photodiode setup to perform off-microscope 
detection; and fractal analysis. It concludes with a discussion about performance in serum 
and possibilities for future work. 
Chapter 2 will discuss the beginning of the idea of magnetorotation for 
biosensing, Label-Acquired Magnetorotation (LAM). LAM involves two primary 
components: a 10 μm nonmagnetic “mother sphere,” and a 1 μm superparamagnetic 
“daughter bead.” The mother sphere and daughter bead are coated with a sandwich pair 
of affinity molecules. The mother sphere is labeled with the capture molecule, and the 
daughter bead is labeled with the detection molecule. In the performance of LAM, a 
solution containing the mother spheres is mixed with a solution containing the target of 
interest. After this initial capture step, the detection step is performed by the addition of 
the superparamagnetic daughter beads to the solution. If the target has been captured on 
the surface of the mother spheres, the daughter beads will bind to the target on the surface 
of the mother sphere. In this manner, the mother sphere is covered with labeling daughter 
beads in proportion to the concentration of protein in solution. The mother sphere has 
“acquired” the daughter beads through the presence of the target bound to its surface. In a 
rotating magnetic field, the rotational frequency of a mother sphere is proportional to the 
number of daughter beads attached to it. Specifically, the target was a 40 nm biotinylated 
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nanoparticle, and the affinity molecules were streptavidin. This biotin-streptavidin setup 
was used to mimic the presence of a real affinity-molecule—protein pair, for the initial 
development and proof-of-principle of this concept. 
Chapter 3 extends LAM to the next step by using a real affinity-molecule—
protein pair. The protein thrombin, a blood coagulation co-factor, along with two 
aptamers, known as the 15-mer and the 29-mer, against thrombin as the affinity 
molecules, are used. The same basic mother sphere and daughter bead LAM model of 
Chapter 2 is used. Results are shown with a limit of detection (LOD) down to below 1 
nM in buffer for thrombin. Additionally, simulation results are shown showing the 
potential for improvement in the system.  
Chapter 4 introduces a new model, called Bead Assembly Magnetorotation 
(BAM), which is the second generation of LAM. The same thrombin and aptamer system 
from Chapter 3 is used. The 10 μm mother sphere is removed from the system, and only 
1 μm daughter beads are used. Half of the daughter beads are coated with the capture 
aptamer, and the other half of the daughter beads are coated with the detection aptamer. 
Instead of creating many mother spheres with beads attached to them, an inverted droplet 
is used to concentrate all the beads in the droplet into a single assembly, composed of 
between hundreds to thousands of beads. The size and shape of the assembly determine 
its response to a rotating magnetic field. If the concentration of the protein in solution is 
high, then as the beads fall to the center of the droplet, they will bind to each other, and 
be unable to tightly aggregate at the center of the droplet; the assembly will be loosely 
packed, with a lot of void space within it. If the concentration of the protein is low, then 
as the beads fall to the center of the droplet, they will not bind to each other via thrombin 
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chains, but will reach the center of the droplet and the assembly will be densely packed. 
The higher the packing density of the assembly, the greater its rotational period in a 
rotating magnetic field will be. This method was shown to be extremely sensitive, with a 
limit of detection of 80 fM in buffer, which is one of the lowest ever reported with this 
very popular aptamer-protein pair. In addition to magnetorotation, a second signal 
transduction mechanism was developed, fractal analysis. By performing an analysis of 
images of the bead assemblies, the fractal dimension and lacunarity could be determined, 
which proved as well to be good indicators of the concentration of protein in solution, 
though with a higher LOD. Finally, a laser-and-photodiode setup was developed, to allow 
for portable, microscope-free detection of magnetorotation. This setup proved to be 
robust, and could form the basis for the development of a portable point-of-care detection 
setup for the performance of BAM.  
Chapter 5 discusses the attempts to translate BAM to serum analysis. The final 
step in demonstrating the potential of BAM as a clinically relevant technology is its 
translation into serum. The experiments described in the previous three chapters were 
performed in buffer, but for the work described in this chapter we attempt to perform 
BAM in serum. The primary challenge with working in serum is mitigating nonspecific 
interactions between serum proteins and the beads. The strategy we used to mitigate these 
interactions was functionalizing the beads with poly(ethylene glycol) (PEG). PEG is an 
extremely hydrophilic molecule that is frequently used for this purpose. PEG was shown 
to be fairly effective at mitigating interactions between serum proteins and the beads. 
However, significant nonspecific-binding interactions also occurred between the 
aptamers and serum proteins, which were harder to mitigate, and which we believe are 
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due to the basic structure of the thrombin aptamers. Due to the high level of nonspecific 
binding between the aptamer and the serum proteins, the LOD was reduced by about four 
orders of magnitude when transitioning from buffer to serum; however, BAM still 
remained competitive with the leading reports of thrombin detection in serum. An 
unexpected challenge was encountered due to the collapse of the assemblies during 
magnetorotation, which we suspect is due to the high flexibility of the PEG molecule 
compared to the relatively rigid aptamer.  
Chapter 6 discusses a project that is different from the rest of the work in this 
dissertation. As part of the conditions of the fellowship which supported the first three 
years of my research at Michigan, I spent a summer as an intern at Sandia National Labs 
in Livermore, CA. While there, I explored a concept related to the rest of the work in this 
dissertation, which is the use of aptamers in capillary electrophoresis, which is a different 
type of signal transduction mechanism. This project is connected to the rest of the work 
in this dissertation because it studied aptamers for diagnostic purposes, and the 
challenges associated with their use in serum. The knowledge and understanding of 
aptamers that was gained in this project informed much of the work that was conducted 
in the rest of this dissertation. This project studied the role of aptamers as affinity 
reagents in capillary electrophoresis towards an integrated lab-on-a-chip platform. The 
target analyte being studied was the nuclear transcription factor NF-κB. The affinity 
molecule used was a single fluorescently-labeled aptamer. This project shows that 
aptamers are generally better suited than antibodies to be affinity molecules in capillary 
electrophoresis, because they typically posses a much smaller mass than antibodies 
(approximately 10-20 kDa for aptamers, 150 kDa for antibodies). Since capillary 
16 
 
electrophoresis is based on the difference between the mass of the free affinity molecule 
and the mass of the affinity molecule-target complex, a smaller affinity molecule results 
in better signal resolution. Additionally, the problem of nonspecific interference from 
serum proteins was solved by the addition of an excess of nonspecific aptamer. Finally, 
the use of an on-chip preconcentration membrane was shown to increase the sensitivity of 
the system.  
At the end of this dissertation, two appendices are included that discuss additional 
experimental avenues that were explored. The first discusses attempts to perform BAM in 
larger droplets, which calculations suggested would lower the LOD, but were 
unsuccessful due to the presence of convection currents within these larger droplets. The 
addition of glycerol to the droplets as a way to mitigate the currents was investigated. The 
second discusses the exploration of two potential signal transduction methods, the angles 
between adjacent beads within an assembly, and the radius of gyration of the assembly, 
that ultimately were not as useful as the other methods discussed in this dissertation.  
Overall the work presented in this dissertation discusses the development of 
magnetorotation as a protein diagnostic tool, as well as some of the challenges associated 
with using aptamers as affinity reagents in serum, and potential strategies for mitigating 
them. The LOD obtained for the protein thrombin in buffer is one of the best LODs 
reported for this protein-aptamer combination, which demonstrates the potential of 
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Label-Acquired Magnetorotation for Biosensing: A Magnetic Label Induced 
Asynchronous Rotation Biosensor 
 
Introduction 
Magnetic microbeads have been used in a variety of methods as labels to indicate 
the presence of a biological molecule. [1-3] The basic structure of these assays involves 
capturing the target of interest, either an antigen or an antibody, on a surface, and using 
antibody-labeled magnetic beads or particles to bind to the target. The presence of the 
magnetic labels can be measured in a variety of ways, including changes in 
magnetoresistance, [4, 5] relaxation time, [6, 7] translational motion, [8, 9] and particle 
agglutination. [10-12] In this chapter, we demonstrate label-acquired magnetorotation, in 
which the target facilitates the binding of magnetic label beads to a nonmagnetic sphere, 
and the rotational frequency of the resulting sandwich complex in a rotating magnetic 
field depends on the number of attached magnetic label beads. Label-Acquired 
Magnetorotation (LAM) is based on the principles of Asynchronous Magnetic Bead 
Rotation (AMBR), where magnetic particles rotate at a different rate than that of a 
driving magnetic field. AMBR has previously been used in our lab to measure magnetic 
properties of magnetic particles, [13] dynamic viscosity, [13] detect bacterial cells with 
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single cell sensitivity, [14] and for designing a portable sensor. [15] Asynchronous 
rotation of microparticles has also been studied in a variety of other systems. [16-27] 
 Superparamagnetic beads, which here are micron-sized beads, each typically 
composed of an inert polymer sphere embedded with superparamagnetic nanoparticles, 
have several advantageous properties for use as labels. [2] The magnetic material of the 
superparamagnetic beads is stable over time, and the beads are stable over long term 
storage and under most physiological conditions.  Biological samples typically have little, 
if any, naturally occurring magnetic material, thus reducing the likelihood of background 
interference (with the exception of rare counterexamples, such as magnetotactic bacteria 
[28]). Superparamagnetic beads are readily manipulated by external magnetic fields, and 
can be quantitatively detected by a variety of methods. 
Sandwich immunoassays are common assay techniques used to detect biological 
molecules. A sandwich assay includes three components: a solid phase to isolate the 
analyte from solution; the analyte itself; and a label or indicator, which binds specifically 
to the analyte. This results in the analyte being “sandwiched” between the solid phase and 
the label [29]. Some of the more frequently used labels include fluorescent molecules, 
enzymes, and superparamagnetic beads. [30-32] Here we perform a sandwich assay on 
the surface of a non-magnetic sphere with superparamagnetic beads as labels. 
Micron-scale spheres, particles and magnetic beads, are readily available 
commercially, in a variety of sizes, coated with biotin or streptavidin, making them an 
ideal model system for developing new immunoassays. Streptavidin is a tetrameric 
protein (MW ~ 60 kDa) isolated from the bacteria Streptomyces avidinii, and forms a 
very strong noncovalent bond (Kd ≈ 10-15 M) with the biomolecule biotin (MW ~ 244). 
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[33] This protein pair has been used previously to develop spin valve sensors [34] and 
photonic surface crystal wave [35] assays. In this chapter, the biotin-coated particles 
serve as a mimic for a biological analyte. In future work, biotin and streptavidin will be 
replaced by proteins and antibodies of clinical interest.  
A schematic of the sensor is shown in Figure 2.1. The setup consists of three 
components: 6.7 μm streptavidin-coated solid phase spheres, 40 nm biotin-coated 
particles serving as an analyte mimic, and 1 μm streptavidin-coated superparamagnetic 
label beads. This figure demonstrates the concept of label-acquired magnetorotation: the 
sandwich complex rotates only when it has acquired magnetic labels. To the best of our 
knowledge, this design represents the first combination of label-acquired magnetic 





Figure 2.1—Schematic of the design of label-acquired magnetorotation. (a) The three 
components of the sandwich assay are shown, the solid phase sphere (6.7 μm streptavidin 
coated sphere), the analyte mimic (40 nm biotin-coated particle) and the label (1 μm 
streptavidin-coated superparamagnetic bead). Streptavidin is a 60 kDa tetrameric protein, 
and is represented by the cloverleaf symbol in the schematic, while the actual structure of 
biotin is shown. (b) Initially, the analyte is incubated with the spheres in a 
microcentrifuge tube. Following removal of the unbound analyte, the solution is 
transferred to a square-bottom 384-well plate, where the spheres are incubated with 
magnetic beads that bind selectively to the analyte, which forms a sandwich complex. (c) 
In the presence of a rotating magnetic field of constant magnitude, where ,= ×τ m B the 
rotational torque exerted on the sphere, and hence its rotational frequency, is a function of 
the number of attached superparamagnetic label beads. 
 
Materials and Methods 
 1x Dulbecco’s Phosphate-Buffered Saline (PBS) was obtained from MP 
Biomedicals (Solon, OH). Tween-20 was obtained from Acros Organics (Geel, Belgium). 
10% Bovine Serum Albumin (BSA) Blocker solution was obtained from Pierce 
28 
 
(Rockford, IL). 6.7 μm streptavidin-coated polystyrene solid phase spheres (Spherotech, 
Lake Forest, IL), with density ρ = 1 g/cm3, were washed three times by centrifuging and 
discarding the supernatant. The spheres were then resuspended and diluted 1:10 in a PBS 
solution that contained 0.1% Tween-20 and 0.1% BSA (which will be referred to as PBS-
TB) to reduce nonspecific adsorption, resulting in a final concentration of 3.02 x 103 
spheres/μL. 40 nm yellow-green fluorescent biotin-coated particles (Invitrogen, Carlsbad, 
CA) were diluted in PBS-TB to final concentrations ranging from 1.62 x 105 particles/μL 
to 5.12 x 107 particles/μL. 10 μL of the diluted 6.7 μm streptavidin-coated solid phase 
spheres were mixed with 10 μL of each biotin-coated particle solution and incubated end-
over-end on a Sarmix SR1 (Sarstedt, Numbrecht, Germany) rotating mixer for 18 hours. 
Excess biotin-coated particles were removed by centrifuging the solution and discarding 
the supernatant three times, and the sample was then resuspended in PBS-TB. (This step 
was necessary because free biotin-coated particles would cause the streptavidin-coated 
superparamagnetic label beads to clump.) Successful binding and washing was confirmed 
by fluorescent microscopy with a 488 nm wavelength light excitation.  
 1 μm Dynal T1 streptavidin-coated superparamagnetic label beads (Invitrogen), ρ 
= 1.8 g/cm3, were washed three times, and were then resuspended and diluted 50x in 
PBS-TB, for a final concentration of 1.94 x 105 beads/μL. 2 μL of the biotin-coated 6.7 
μm spheres and 2 μL of the 1 μm streptavidin-coated superparamagnetic label beads were 
mixed and diluted with 26 μL of PBS-TB, and then transferred to a well on a non-binding 
surface 384-well plate (Corning, Corning, NY). The components were incubated at room 
temperature for 4 hours.  The 1 μm streptavidin-coated superparamagnetic label beads 
bound to the exposed biotin-coated particles on the 6.7 μm streptavidin-coated solid 
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phase spheres, forming a sphere-particle-bead sandwich complex. A coverslip fluidic cell 
was fashioned between two 22 x 40 mm No. 0 thickness coverslips (Pierce, Rockford, IL) 
separated by a single piece of double-sided clear tape (3M, St. Paul, MN). The sandwich 
complexes were transferred from the 384-well plate and pipetted into the coverslip fluidic 
cell. The ends of the fluidic cell were sealed with Apiezon L grease (Apiezon, 
Manchester, UK) to prevent drift and evaporation. 
A schematic of the experimental setup is shown in Figure 2.2. A rotating 
magnetic field was created with a pair of orthogonal Helmholtz coils that fits onto an 
inverted microscope. One pair of coils was driven by a sine wave, and the other pair was 
driven by a cosine wave, generating a uniform rotating magnetic field between the coils. 
The driving frequency and amplitude were controlled by an in-house custom-built 
function generator and amplifier. The field in the center of the coils was 1 mT rotating at 
a frequency of 20 Hz, as measured by a 3-axis magnetic field transducer (SENIS GmbH, 
Zurich, Switzerland). The rotation of the spheres was observed using two setups. The first 
was an Olympus IMT-2 inverted microscope (Olympus, Melville, NY) connected to a 
Photometrics Cool Snap ES camera (Roper Scientific, Trenton, NJ). Videos were 
recorded on a computer using MetaMorph (Meta Imaging Software, Downington, PA). 
The second was an Olympus IX71 inverted microscope with an oil-immersion 100x 
objective connected to a Basler pIA640-210gm camera (Basler, Highland, IL). Videos 
were recorded on a computer using an in-house program written in LabVIEW (National 
Instruments, Austin, TX).Videos were analyzed using the St. Andrews particle tracker 
(with custom modification to allow for tracking of angular orientation), [36] a 




Figure 2.2—Schematic of the setup used in this chapter. Sandwich complexes are 
pipetted into a coverslip fluidic cell. A rotating magnetic field is created by two 
orthogonally oriented Helmholtz coils with each coil wrapped with 90 turns of copper 
wire. The field is controlled by a function generator and an amplifier. Parallel coils are 
considered part of a “pair.” The pairs are driven 90˚ out of phase with each other. The 
spheres are observed through 60x and 100x objectives connected to a digital camera. 




For a magnetic object actively rotating in a fluid, the magnetic torque (
mag 0µ= ×τ m H ) and the rotational fluidic drag ( drag d dtτ γ θ= ) oppose each other, and 
are the primary factors determining the rotational dynamics. The magnetic torque is 
composed of the induced (e.g. paramagnetic and superparamagnetic) and permanent (e.g. 
ferromagnetic) magnetic moments of the bead. This relationship is expressed below 
 drag mag= −τ τ  (2.1) 
 mag ind perm= +τ τ τ  (2.2) 
 ( )ind perm 0ddt
θγ µ= + ×m m H  (2.3)   
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where mind is the induced magnetic moment of the bead, mperm is the permanent magnetic 
moment of the bead, μ0 is the permeability of free space, H is the magnetizing field, γ is 
the drag coefficient, θ is the angular orientation of the object, and dθ/dt is the rotational 
rate in radians/s. Note that for this case, other torques, such as inertial and Brownian, are 
neglected. For a rotating body, γ = κηVH, where κ is the shape factor (equal to 6 for a 
sphere), η is the dynamic viscosity, and VH is the volume of the rotating body.  The 
magnetic torque arising from the induced magnetic moment can be obtained by 
combining the relationships mind = MVm and M = χH, where M is the magnetization of 
the material, χ is the magnetic susceptibility and Vm is the magnetic volume. In a rotating 
magnetic field, the magnetic susceptibility can be separated into real and imaginary parts 
χ = χ’ – iχ”, corresponding to in-phase and out-of-phase components of the 
magnetization.  When the above relationships are substituted into ind ind 0µ= ×τ m H and 
the cross product is carried out (namely 2( )i Hχ χ χ′ ′′ ′′− × =H H H ), one arrives at 
equation (2.4), which describes the torque arising from induced magnetic moment: 
 20ind mV Hµ χ′′=τ . (2.4) 
The torque arising from the permanent moment in a rotating magnetic field can be 
expressed as: 
 ( )perm perm 0 0 sinm H tµ µ θ= × = Ω −τ m H  (2.5) 
where t is time and Ω is the rotational frequency of the field. Combining equations (2.1) – 
(2.5) yields  
 ( )20 0 sinm
d V H m H t
dt
θ µ χγ µ θ′′= + Ω −  (2.6) 
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Equation (2.6) describes the behavior of the rotating sandwich complex, composed of 1 
μm superparamagnetic beads (with a small ferromagnetic component), in a rotating 
magnetic field.  
The magnetic beads used in this study are composed of 1 μm polymer spheres 
embedded with superparamagnetic nanoparticles. In the presence of a magnetic field, the 
magnetic moments of these nanoparticles align with the field and then undergo Neel 
relaxation. If the frequency of a rotating field is sufficiently high, the magnetic behavior 
is dominated by the imaginary susceptibility, which has been discussed in detail in the 





θ µ χγ ′′=  (2.7) 
When dealing with only permanent magnetic dipoles, equation (2.6) reduces to:  
 ( )0 sin
d m H t
dt
θγ µ θ= Ω −  (2.8) 
As has been previously shown, [18, 37] this equation can be analytically solved. 
 
Theory for Rotating Sandwich Complex 
For the frequency and magnetic field amplitude used in this chapter, 20 Hz and 1 
mT, the rotation rate scales with the square of the magnetic field amplitude, as given by 
2/d dt Hθ ∝  (data not shown). Additionally, the rotation rate increases with increasing 
driving frequencies, Ω. Both observations indicate that, under these conditions, the 
induced moment of the beads dominates over their permanent moment and is the primary 







∝  (2.9)    
where the changes in the hydrodynamic volume and the shape factor are assumed to be 
negligible. For a collection of particles with induced dipoles, the total moment is simply 
the sum of the individual induced moments of each particle. Therefore, equation (2.9) can 





∝  (2.10) 
This dependence can be seen in Figure 2.5b, and equation (2.8) holds for materials that 
do not have permanent dipoles. Equation (2.10) establishes that the rotational frequency 
in Hz (e.g. (1/2π)*(dθ/dt)) of a sandwich complex in a rotating magnetic field is a 
function of the number of 1 μm superparamagnetic beads in the rotating sandwich 
complex. Since the beads attach proportionally to the concentration of the analyte, we can 
rewrite equation (2.10) as   




    
 
Indeed, this general behavior of increased rotational rate with increased analyte coverage 
is observed over two orders of magnitude as shown in Figure 2.6 and is discussed in 
detail below. 
 
Results and Discussion 
Sandwich complex assays were performed with biotin-coated particles as the 
analyte, which mimic a biological target. The concentration of biotin-coated particles was 
measured by observing the rate of rotation of the (solid phase sphere)-(biotin-coated 
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particle)-(superparamagnetic label bead) sandwich complex. The 6.7 μm solid phase 
sphere has a surface area of 141 μm2. Given that a 40 nm biotin-coated particle would 
occupy an area of 1.26 x 10-3 μm2, one 6.7 μm sphere could bind up to 105 biotin-coated 
particles. The superparamagnetic label beads have a diameter of 1 μm, and occupy an 
area of 0.866 μm2, which, given the limits of the packing efficiency of spheres, suggest 
that 145 superparamagnetic label beads can bind to that surface. This configuration 
would be expected to produce a sensor with approximately 2 orders of magnitude of 
dynamic range, as indicated by equation 2.5, assuming that the magnetic moments of the 
beads are additive. The position at which the beads bind to the sphere should mostly 
affect the rotation at low numbers of binding beads. A variation in the binding location of 
a few beads could affect the rotational speed, which would result from differences in 
location-dependent torque and drag. However, as the number of beads on the sphere 
increases, this effect will have a smaller contribution. A full theoretical investigation into 
the specifics of this effect warrants further study, potentially using Hydro++, [38] but is 
beyond the scope of this chapter. Furthermore, the 6.7 μm “mother” sphere is more than 
300 times bigger than a 1 μm label bead, thus the binding of a single bead to the sphere 
should not significantly alter the sphere’s center of rotation or shape factor.  Size 1 μm 
beads were selected as labels for these experiments so that they could still be individually 
distinguished by using optical microscopy.  
 Scanning electron micrographs of the sandwich complexes are shown in Figure 
2.3. The three complexes shown were from samples with total biotin-coated particle 
concentrations of 2.88x 107 particles/μL, 2.88x 106 particles/μL, and 2.88x 105 
particles/μL, respectively. Figure 2.3a shows a reasonably dense coverage of the sphere 
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by the superparamagnetic label beads, while Figure 2.3b shows fewer beads, and figure 
2.3c show only two beads. This trend confirms that a greater number of 




Figure 2.3—Scanning electron micrographs of sandwich complexes incubated with three 
different concentrations of biotin-coated particles, (a) 2.88 x 107 μL-1, (b) 2.88 x 106 μL-1, 
and (c) 2.88 x 105 μL-1. 1 μm superparamagnetic label beads can be seen attached to the 
surface of the 6.7 μm solid phase spheres. The structures in the background of these 
images likely resulted from salts left by the buffer after evaporation. 
 
 The frame-by-frame analysis of sandwich complexes, from four 15 seconds 
videos recorded at 20 frames per seconds, is shown in Figure 2.4a. The angle of the 
sandwich complex in each frame is calculated against the first frame in the video, which 
is defined as the zero angle. One complete rotation is 360 degrees. The sandwich 
complexes occasionally were out of focus, which caused the tracker to mistrack the 
complexes for those frames. These outlying points were removed from Figure 2.4a, based 
on calculating the jackknife residuals for each point and discarding outliers whose 
residuals exceeded the Bonferroni criteria. [39] The MATLAB code for performing this 
procedure is included in Appendix C-1.The four videos represent sandwich complexes 
with rotational frequencies of 133 mHz, 231 mHz, 303 mHz, and 396 mHz. The traces 
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demonstrate the stability and consistency of the rotation of a sandwich complex during a 
15 second observational period. 10 frames from each of the four videos, 0.5 seconds 




Figure 2.4—Examination of the behavior of individual sandwich complexes. (a) Frame-
by-frame analysis of four different rotating sandwich complexes. The angle at each time 
point represents the number of degrees through which the complex has rotated since t0 
(360˚ represents one full rotation). The rotational frequency of the complex is shown 
above each trace. (b) Ten frames from each of the videos in part (a), in 0.5 second 
intervals. The top sandwich complex completes about 1.75 rotations over the 10 frames, 
while the bottom sandwich complex completes about 0.75 rotations over the 10 frames. 
The driving frequency is 20 Hz for all samples. Scale bar is 5 μm. 
 
The stability of the rotational frequency of sandwich complexes was also 
measured. Sandwich complexes were observed for 60 minutes, with 15 second videos of 
the rotating complex captured every five minutes. Eight sandwich complexes were 
observed in total; four adhered to the coverslip before the end of the 60 minutes, and 
were excluded from the analysis. The use of PBS-TB decreased nonspecific adherence to 
the coverslips, but did not completely prevent it. The average (±SD) rotational 
frequencies of the four complexes determined from the videos over the observational 
period are: 124.1 ± 6.2 mHz, 203.3 ± 5.1 mHz, 302.1 ± 4.2 mHz, and 410.8 ± 6.3 mHz. 
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The rotational frequencies of the four sandwich complexes are shown in Figure 2.5a, and 




Figure 2.5—(a) The stability of the rotation of a sandwich complex over time. The 
rotational frequency of the complex was obtained every five minutes over a sixty minute 
observational period. The mean ± standard deviation of the rotational frequency for the 
four complexes over the observational period is 124.1 ± 6.2 mHz, 203.3 ± 5.1 mHz, 
302.1 ± 4.2 mHz, and 410.8 ± 6.3 mHz. (b) Relationship between the rotational 
frequency of the sandwich complex and the number of attached superparamagnetic beads. 
A linear trendline fits the data (r2 = 0.649). Note that a sandwich complex will rotate with 
as little as two attached beads. 
 
 The behavior of individual sandwich complexes was found to determine the 
relationship between the rotational frequency and the number of attached 
superparamagnetic label beads. The number of superparamagnetic label beads attached to 
the complex was determined by visual inspection. The rotating magnetic field was then 
turned on, and the rotational frequency of each complex was measured. These results are 
shown in Figure 2.5b. (During observations, it was difficult to distinguish individual 
beads when more than 40 were on a solid phase sphere, so complexes with more than 40 
attached beads were excluded from this analysis.) It should also be noted that a complex 
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will rotate with as little as two attached superparamagnetic label beads, which suggests 
that the theoretical lower detection limit of the system could be on the order of a few 
analyte molecules bound to the surface, for this solid phase sphere and magnetic label 
bead combination.  
Having established the stability of the rotation of a sandwich complex, and the 
relationship between rotational frequency and the number of attached superparamagnetic 
label beads, label-acquired magnetorotation (LAM) was then shown to be capable of 
measuring the concentration of biotin-coated particles in solution. Sandwich complexes 
with a range of biotin-coated particle concentrations were prepared as described in the 
experimental section, transferred into a coverslip fluidic cell, and placed in a rotating 
magnetic field. Eight sandwich complexes from each concentration of biotin-coated 
particles were chosen at random and 15 second videos of each sandwich complex were 
recorded. Complexes that adhered to the surface of the coverslip were not considered for 
analysis (the number of attached magnetic labels did not appear to be a factor in 
determining sandwich complex-surface adhesion). The results are shown in Figure 2.6. 
The rotational frequency of the sandwich complex increases with increasing biotin-coated 
particle concentration over the range from 1.62 x 105 to 9.70 x 106 biotin-coated 
particles/μL, and then plateaus at higher concentrations. This plateau is likely due to the 
saturation of the sphere by superparamagnetic beads labels. The lowest detected 
concentration of biotin-coated particles was 2.88 x 105 particles/μL. No formation of 
sandwich complexes, or rotation of the 6.7 μm spheres, was observed in control samples 





Figure 2.6—A log-linear plot of the relationship between rotational frequency of the 
complex and concentration of analyte incubated with the sphere. Each point represents an 
average of eight measurements (±SD).  At high concentrations of biotin-coated particles, 
the sensor saturates and the rotational frequency plateaus. The sensor is linear over its 
dynamic range, indicated by the dashed line, r2 = 0.982. 
 
The results demonstrate that label-acquired magnetorotation can be used to detect 
the presence of biological targets. One of the challenges facing this system is the 
significant size distribution of the beads and spheres, which accounts for the wide 
distributions and large standard deviations in our data (Figures 2.5b and 2.6). When 
comparing one sandwich complex to another, the uniformity of the solid phase is 
important. The 6.7 μm solid phase spheres had a coefficient of variability in the diameter 
of 5.8 % as determined by fluorescent activated cell sorting. [40] Since the rotational 
frequency of the sphere depends on volume, this results in up to a 17.4 % variability in 
rotational frequency. Additionally, the superparamagnetic label beads, composed of 
magnetic nanoparticles embedded in a 1 μm non-magnetic bead, exhibit significant bead-
to-bead variability. 2.8 μm superparamagnetic beads from the same manufacturer have 
been reported to have a variability in magnetic responsiveness (a combination of bead 
magnetic moment and shape factor) on the order of 30%, [41, 42] and observations in our 
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lab suggest a similar variability for the 1 μm beads. These high variabilities could be 
reflected by the data presented in Figure 2.5. Despite the variabilities, averaging through 
multiple samples allows for validation of this new method.  
 The potential sensitivity of this method was indicated by the rotation of a 
sandwich complex which was observed after the attachment of just two 
superparamagnetic label beads. The system described here presents a number of potential 
advantages for diagnostic applications, and we are exploring a number of avenues that 
could turn this new method into a clinically useful technology. We envision that label-
acquired asynchronous magnetic bead rotation will be used in future diagnostic devices. 
Such a system could be applied to detect a wide range of biological targets, including 
proteins, viruses, bacteria and cancer cells, or any other target associateable with an 
affinity molecule. Currently, work is underway on label-acquired magnetorotation for the 
detection of antigens with antibodies, using a photodiode and a laser for monitoring 




 This chapter presents a proof-of-principle for a new kind of biosensor, based on 
label-acquired asynchronous magnetic bead rotation. The sensor is based on a sandwich 
assay, with a nonmagnetic sphere as the solid phase and superparamagnetic beads as the 
analyte labels and utilizes asynchronous magnetic bead rotation (AMBR). The rotational 
frequency of the sandwich complex in a rotating magnetic field depends on the 
concentration of the analyte present in the solution. This sensor demonstrates the 
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potential for a simple and sensitive technique, with two orders of magnitude in dynamic 
range, which we hope would improve upon parameter optimization. Although further 
work remains to be done, this system exhibits potential for integration with other 
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Label-Acquired Magnetorotation as a signal transduction method for protein 
detection: aptamer-based detection of thrombin 
 
Introduction 
One of the primary goals in a point-of-care diagnostic system is measuring the 
concentration of a protein in order to assess the overall health of a patient. Effective 
screening methods have been shown to improve patient health, such as a recent large 
study, on a population at high risk for lung cancer, which found a 20% decrease in 
mortality due to better early screening. [1, 2] There are three primary components in a 
protein measurement system: the target biomarker to be measured, the affinity molecules 
used to capture the target, and the method of transducing a successful binding event into a 
quantifiable signal. There are several popular signal transduction methods, including 
optical, electrochemical and magnetic schemes. This chapter presents the continued 
development of the optomagnetic signal transduction method, called Label-Acquired 
Magnetorotation (LAM), which has the potential for eventual incorporation into a point-
of-care diagnostic system. Previously, we published proof-of-principle work 
demonstrating the concept of LAM using a biotin and streptavidin system as protein and 
aptamer mimics. [3] Here, we demonstrate the next step by showing LAM used to detect 
proteins in solution using aptamers. 
48 
 
The most common set-up for measuring the concentration of a protein in solution 
is the sandwich assay, where the target is first captured by an affinity molecule bound to 
a surface, and is then sandwiched by a signal transducer attached to another affinity 
molecule. [4] Optical methods include sandwich-based ELISA, [5-7] fluorescence 
signaling [8-10]  or quantum dots, [11, 12] and the non-sandwich based surface plasmon 
resonance methods. [13-15] The electrochemical methods include sandwich-based 
amperometric enzymatic methods [16, 17] and non-sandwich-based impedimetric 
sensing. [18, 19] 
Magnetic beads are advantageous for use as signal transducers because they are 
biologically inert, are physically stable under most biological environments, and 
biological materials have no native magnetism that could interfere with a signal from the 
beads. [20, 21] Due to these advantages, magnetic beads have been used as signal 
transducers in a variety of applications, including giant magnetoresistance (GMR), [22-
24] Hall probes, [25, 26] and magnetic relaxation. [27, 28] Additionally, magnetic beads 
have been used as carriers for magnetophoresis and to facilitate detection by other signal 
transduction methods. [29-31] In contrast, the method described here uses optical 
detection of the magnetic behavior. 
The beads used in this study are 1 μm commercial beads that exhibit 
superparamagnetic behavior (DynaBeads®). These beads are composed of maghemite (γ-
Fe2O3) nanoparticles, with a mean diameter of 8 nm dispersed within a polymer bead. 
The beads are 25.5% Fe by mass. [32] In the absence of a magnetic field, these beads 
have no net magnetization, but within a magnetic field, the magnetic moments of the 
beads align with the field and they become strongly magnetic. [32]  
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The work presented here uses these beads in a rotating magnetic field. Previous 
studies have examined and characterized the behavior of these beads in alternating 
magnetic fields. It was first shown that in a one-dimensional alternating magnetic field, 
the dominant relaxation mechanism of such superparamagnetic beads is the Neel 
relaxation of the nanoparticles embedded within the bead. [33] It was later shown that in 
a two-dimensional rotating magnetic field, at high driving frequencies, the dominant 
mechanism driving the rotation of these same beads is also related to Neel relaxation. 
[34] Brownian rotational effects are not significant for these beads because the time 
constant for the Brownian relaxation of a sphere with diameter on the order of a micron is 
on the order of seconds, while the time constant for the Neel relaxation of the inner 
magnetic nanoparticles is on the order of nanoseconds. 
In a two-dimensional rotating magnetic field, at low driving frequencies, magnetic 
beads are able to rotate synchronously with the field. At higher driving frequencies 
(above the critical frequency [35]) these beads are not able to stay in phase with the field, 
and rotate asynchronously. In the asynchronous regime, the rotational frequency of the 
bead depends on a number of factors, including the magnetic moment of the bead, the 
amplitude and frequency of the driving field, the hydrodynamic volume of the bead, and 
the viscosity of the solution. This asynchronous rotation has already been demonstrated 
to be a useful tool for making biological measurements, specifically for monitoring the 
growth and antibiotic susceptibility of bacteria. [36-39] 
            Thrombin is a coagulation factor that is the first step in the coagulation cascade 
that leads to the formation of a blood clot, so as to stem blood loss. Aptamers are single- 
or double-stranded nucleic acid sequences that bind to proteins through favorable 
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electrostatic interactions, with an affinity similar to that of an antibody. [40, 41] One of 
the earliest aptamers to be identified binds to the fibrin exosite on thrombin, and has the 
following 15-base pair sequence: 5’-GGTTGGTGTGGTTGG-3’. [42]   Later, a second, 
29-base pair sequence against thrombin was identified, which binds to the heparin 
exosite: 5’-GTCCGTGGTAGGGCAGGTTGGGGTGAC-3’. [43] Since these aptamers 
bind to opposite sides of the thrombin molecule, they represent an ideal system for the 
development of an aptamer-based sandwich assay, and have been used in the 
development of many such assays. [44-46]  
 
Materials and Methods 
A schematic of LAM is shown in Figure 3.1. The mother spheres used were 10 
μm nonmagnetic streptavidin-coated ProActive microspheres (Bangs Labs, Fishers, IN). 
The daughter beads used were Dynal MyOne 1 μm streptavidin-coated DynaBeads that 
exhibit superparamagnetic behavior (Invitrogen, Carlsbad, CA). Human α-thrombin was 
purchased from Haematologic Technologies (Essex Junction, VT). Biotinylated aptamers 
(with a 5’ polyT20 tail for improved binding)[47] were purchased from Integrated DNA 
Technologies (Coralville, IA). Salts (NaCl, KCl, MgCl2, EDTA and Tris-HCl) and 
Tween-20 were purchased from Sigma Aldrich (St. Louis, MO). Bovine serum albumin 
(BSA) Blocker solution was purchased from Thermo Scientific (Waltham, MA). Zero-
thickness glass coverslips were obtained from Electron Microscopy Sciences (Hatfield, 
PA). OPI Top Coat clear nail protector was purchased from OPI Products Inc. (North 
Hollywood, CA). Formulations for wash buffer, aptamer binding buffer, and thrombin 
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binding buffer (containing 0.1% BSA, and with the addition of 10 mM KCl [48]) were 
based on previously published work. [47] 
 
 
Figure 3.1—Schematic of LAM with thrombin as the analyte. (1) 10 μm nonmagnetic 
mother spheres coated with the 29-mer anti-thrombin aptamer are mixed with thrombin, 
which binds to the mother spheres. (2) 1 μm magnetic beads coated with the 15-mer anti-
thrombin aptamer are mixed with the thrombin-coated mother spheres. The magnetic 
beads bind to the thrombin attached to the mother sphere, forming a sandwich complex. 
(3) The sandwich complex is transferred to a rotating magnetic field, where the rotational 
frequency of the sandwich complex depends on the number of attached magnetic beads. 
 
An aliquot of 50 μL of the magnetic beads was washed three times by magnetic 
separation in 200 μL of wash buffer, and then resuspended in 500 μL of aptamer binding 
buffer, at a concentration of 1 mg/mL beads in a microcentrifuge tube. An aliquot of 50 
μL of the mother spheres was washed three times by centrifugation in 200 μL of wash 
buffer, and then resuspended in 1 mL of aptamer binding buffer, at a concentration of 0.5 
mg/mL spheres. A 10 μL aliquot of biotinylated-15-mer thrombin binding aptamer was 
added to the superparamagnetic beads, and a 10 μL aliquot of biotinylated-29-mer 
thrombin binding aptamer was added to the mother spheres. The two solutions were 
briefly vortexed then incubated on an end-over-end rotator for 1 hour. They were then 
washed (by magnetic separation and centrifugation, respectively) three times and 
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resuspended in thrombin binding buffer. An aliquot of human α-thrombin was serially 
diluted over a concentration range of 50 nM to 100 pM in thrombin binding buffer. In a 
separate tube, 100 μL of thrombin solution were mixed with 40 μL of mother sphere 
solution, and then incubated on an end-over-end rotator for 90 minutes. Finally, 10 μL of 
magnetic bead solution were added to the mother spheres and thrombin and incubated on 
an end-over-end rotator for 90 minutes. 
Microfluidic flow cells were prepared from two zero-thickness glass coverslips 
(the bottom coverslip was coated with a thin layer of clear nail protector, to reduce 
particle sticking) separated by a single piece of double-sided Scotch tape (3M, St. Paul, 
MN). The solution containing the mother spheres and the magnetic beads was diluted 
with 140 μL of 0.2% Tween-20, and 20 μL of this solution were pipetted into the 
coverslip flow cell. The coverslip flow cell was then placed in a rotating magnetic field 
(amplitude 1.25 mT, frequency 200 Hz) built from two pairs of orthogonally-oriented 
Helmholtz coils driven by a pair of sinusoidal waves 90 degrees out of phase with each 
other. The magnetic field was located on top of an IX71 inverted microscope (Olympus, 
Melville, NY). The rotation of the sandwich complexes was observed through a 100x oil-
immersion objective, imaged through a Basler piA640-210gm camera (Basler, Highland, 
IL) and recorded by an in-house program written in LabVIEW (National Instruments, 
Austin, TX). Videos were analyzed using the St. Andrews particle tracker [49] and an in-







 The theory governing the behavior of superparamagnetic particles and beads in 
rotating magnetic fields has been discussed in detail elsewhere. [3, 33, 34, 50] Briefly, 
starting from the equation for the magnetic torque, = ×τ m B , where m is the magnetic 
moment of the bead and B is the external magnetic field, assuming steady-state rotation 
(allowing for the equating of rotational driving forces with drag forces, H
dV
dt
θτ κη= , 
where κ is the shape factor (equal to 6 for a sphere), η is the viscosity of the surrounding 
fluid, and VH is the hydrodynamic volume), and making some simple substitutions,
0µ=B H , mV=m M , χ=M H and ' ''iχ χ χ= − , (where H is the magnetizing field, μ0 is 
the permeability of free space, M is the volume magnetization, Vm is the volume of the 
bead’s magnetic material, χ is the bead susceptibility, χ’ is the real component of the bead 
susceptibility and χ’’ is the imaginary component of the bead susceptibility) we can get 








=  (3.1) 








, where χ0 is the DC 
susceptibility, Ω is the frequency of the driving field. The definition of Neel relaxation 










, where τ0 is the attempt frequency, K is the anisotropy 
constant (equal to 5 x 104 J/m3 for maghemite nanoparticles [51]), Vp is the volume of the 
maghemite nanoparticles, kB is Boltzmann’s constant, and T is the ambient temperature. 
The magnetic nanoparticles are not perfectly uniform; for a size distribution with n 
intervals, with average nanoparticle volume Vp, the total volume of nanoparticles in the 
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distribution is Vn. The expression for Neel relaxation time, τN, can be substituted into the 
expression for imaginary susceptibility, χ’’, which, along with considering the effects of 
the nanoparticle size distribution, can then be substituted into equation (3.1) to create a 








































, so equation (3.2) can be simplified: 
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Results and Discussion 
 To test whether the sandwich complexes follow the model of equation (3.3), we 
observed the response of the sandwich complexes to changes in amplitude and frequency. 




∝ . Figure 3.2a shows indeed that the rotational frequency of a sandwich complex 
is directly proportional to the square of the amplitude of the driving field. Holding all 
variables constant except for field driving frequency, equation (3.3) reduces to d
dt
θ
∝ Ω . 
Figure 3.2b shows that the rotational frequency of a sandwich complex does increase 
55 
 
with the frequency of the driving field, but it does not exactly demonstrate the linear 
relationship that equation (3.3) suggests. 
 
Figure 3.2—(a) Amplitude response curves showing that the rotational frequency of a 
sandwich complex is proportional to the square of the amplitude of the driving field (with 
B=μ0H). The data are fit with a linear trendline with r2 values of (A) 0.968, (B) 0.995, 
and (C) 0.994. (b) Frequency response curves showing that the rotational frequency of a 
sandwich complex increases with an increase in the frequency of the driving field. 
 
We examined the stability of the rotation of sandwich complexes over 60 minutes 
of observation. The rotational frequency of four sandwich complexes was measured 
every 5 minutes for 60 minutes, as shown in Figure 3.3a. The coefficient of variation 
(standard deviation divided by the mean, times 100%) of the complexes (A-D) was 3.3%, 
2.5%, 1.5% and 1.6%, respectively, demonstrating that the rotation of a sandwich 
complex is fairly stable over a 60 minute observation period. All other measurements 
reported here were made within an hour of the sandwich complexes being injected into 
the coverslip fluidic cell.  
 A dose-response curve of LAM used for measuring the concentration of thrombin 
in solution is shown in Figure 3.3b. At each thrombin concentration, the rotation of 15 
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sandwich complexes was measured, and each point in the figure represents the average of 
those 15 measurements (± standard deviation). The data was fit using the four-parameter 
logistic Hill equation. [52, 53] The dynamic range of the curve extends from about 1 nM 
to about 20 nM. Above 20 nM, the curve plateaus. Below 1 nM, there is still a detectable 
signal down to 300 pM. In the 300 pM to 1 nM range, there was still binding of beads to 
the mother sphere, but there was no significant difference between the different 
concentrations. Below 300 pM, no binding of beads to the mother sphere was observed. 
Similarly, in a control sample (no thrombin), there was also no binding detected. In the 
absence of the aptamers thrombin does not bind to the spheres and  
beads. Figure 3.3b demonstrates the viability of LAM as a tool for measuring the 
concentration of a protein in solution, with an LOD (limit of detection) of 300 pM. 
Screenshots of the rotation of five of the sandwich complexes from Figure 3.3b 
are shown in Figure 3.4. These images show that the number of beads attached to each 
complex increases with the concentration of thrombin, and that the rotational frequency 
of the complexes increases with the number of attached beads. These images also show 
that a qualitative estimate of the protein concentration can be made merely by looking at 






Figure 3.3—(a) The rotational frequency of four sandwich complexes measured every 
five minutes over the course of an hour. The rotational frequency means, ± SD (CV%) of 
the four sandwich complexes (A-D) are 0.0856 ± 0.0028 Hz (3.3%), 0.1523 ± 0.0038 Hz 
(2.5%), 0.263 ± 0.0040 Hz (1.5%) and 0.448 ± 0.0073 Hz (1.6%), respectively. This 
demonstrates that the rotation of the sandwich complexes is stable over time. (b) Dose-
response curve for the detection of thrombin by LAM. The data are fit by a four-
parameter logistic equation (r2 = 0.971). Each data point represents the average ± SD of 
15 sandwich complexes. 
 
 
Figure 3.4—Screenshots of five sandwich complexes taken through a 100x oil-
immersion objective. The thrombin concentration and the rotational frequency of each 
complex are shown below the picture. The number of magnetic beads on and the 
rotational frequency of each sandwich complex appear to increase with concentration of 
thrombin. 
  
 One of the advantages of using the thrombin aptamers is their popularity; many 
groups have used these aptamers for demonstration of signal transduction techniques. 
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When examining other methods that are sandwich-based and use single-step (non-
amplified) methods, reported LODs typically are in the 0.1-1 nM range, including 
electrochemical detection, [18, 47] quantum dots, [11] Si-nanowire FETs, [19] and 
fluorescent molecular beacons. [54] There are many clinically relevant biomarkers found 
in plasma at concentrations around 1 nM. [55, 56] Within this context, we believe that 
LAM is certainly competitive with other detection technologies. Moreover, LAM has the 
advantage of simplicity, robustness and low cost, without requiring sensitive optical 
readers or other expensive and stationary sensing equipment.   
 We generated a model in MATLAB, shown in Appendix C-2, to simulate the 
optimal performance of LAM, assuming perfect mixing and no nonspecific interactions, 
based on a previously reported two-site immunoassay model. [57] Considering only 
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Where P is the protein of interest, Q1 is the capture aptamer, and Q2 is the detection 
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The model is carried out in two parts, capture and detection. In the capture phase, only 
equation (3.4) is considered. After the capture reaction has reached equilibrium, the 
detection phase commences, in which equations (3.4)-(3.7) are all considered. The rate 
constants for the thrombin aptamers were obtained from previously published work. [58] 




[ ] [ ][ ] [ ] [ ][ ] [ ]1 1 1 1 1 4 1 2 4 1 2
d Q
k Q P k Q P k Q Q P k Q PQ
dt − −
= − + − +  (3.8) 
 
[ ] [ ][ ] [ ] [ ][ ] [ ]2 3 2 3 2 2 1 2 2 1 2
d Q
k Q P k Q P k Q P Q k Q PQ
dt − −
= − + − +  (3.9) 
 
[ ] [ ][ ] [ ] [ ][ ] [ ]1 1 1 1 3 2 3 2
d P
k Q P k Q P k Q P k Q P
dt − −
= − + − +  (3.10) 
 
[ ] [ ][ ] [ ] [ ][ ] [ ]1 1 1 1 1 2 1 2 2 1 2
d Q P
k Q P k Q P k Q P Q k Q PQ
dt − −
= − − +  (3.11) 
 
[ ] [ ][ ] [ ] [ ][ ] [ ]2 3 2 3 2 4 1 2 4 1 2
d Q P
k Q P k Q P k Q Q P k Q PQ
dt − −
= − − +  (3.12) 
 
[ ] [ ][ ] [ ][ ] ( )[ ]1 2 2 1 2 4 1 2 2 4 1 2
d Q PQ
k Q P Q k Q Q P k k Q PQ
dt − −
= + − +  (3.13) 
  
The simulated dose-response curve based on this model is shown in Figure 3.5. 
Deviations of the experimental data from this simulated dose-response curve could be 
due to nonspecific interactions between the aptamers and other proteins in solution, 
imperfect mixing, suboptimal aptamer-bead attachment, or experimental error. The rather 
abrupt plateau at the top of the dose-response curve is due to the saturation of the mother 
spheres with magnetic beads before saturation with thrombin; only a few hundred beads 
can bind to the mother sphere, but over a million thrombin molecules could bind to the 
mother sphere. 
It is our long term goal to develop LAM into a signal transduction method that is 
suitable for use in a point-of-care clinical setting. In order to achieve this goal, several 
additional steps must be taken. We plan to translate LAM off the microscope and 
measure the rotation of the sandwich complex using a simple, compact-disc-like, laser-
and-photodiode setup [59], together with automated and self-contained mixing, in a 
microfluidic chip. We also plan to reproduce these results in a biological fluid medium, 
such as serum. We believe that, after additional development, LAM will be an attractive 
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tool for use, because it will not require fluorescence readers or a microscope, and the 
actual detector (the laser and photodiode) would be low-cost.  We recognize that these 
goals will require additional work. The goal of this chapter is to demonstrate the 
feasibility of LAM as a signal transduction method for measuring the concentration of a 




Figure 3.5—Simulated dose-response curve (dotted line) for LAM from a model based 
on the binding kinetics of the aptamers with thrombin. Also included in the plot are 
experimental data (dots), from Figure 3.3b, and a logistic curve fit (dashed line). The 




 In summary, we have demonstrated that label-acquired magnetorotation is a 
viable signal transduction method for measuring the concentration of a protein in 
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solution, with a limit of detection of 300 pM of thrombin when using the classic thrombin 
aptamers. We have shown that the amplitude and frequency response of a sandwich 
complex generally follow the behavior predicted by the equations that describe 
superparamagnetic bead behavior. It is our hope for the future that, with further work, 
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Magnetic beads have several advantages that make them attractive candidates for 
use as biosensor signal transducers, including their biological inertness, physical stability, 
and the absence of competing magnetic signals in biological materials. [1, 2]  A number 
of magnetism-based protein detection techniques have been developed, including giant 
magnetoresistance (GMR) [3-5], magnetic relaxation, [6, 7] Hall Probes, [8, 9] and 
amplification of an optical signal by magnetic rotation. [10, 11] Additionally, there have 
been reports of using proteins to mediate the formation of one-dimensional magnetic 
bead chains. [12, 13] However, to the best of our knowledge, there have been no previous 
reports studying the shape or drag of two-dimensional magnetic microbead assemblies 
for their use as biomarker signal transducers. 
 This work builds on previous reports on the use of asynchronous magnetorotation 
for biological applications. Asynchronous magnetorotation was employed in a sandwich-
type biosensor, where the magnetic beads acted as labels attached to nonmagnetic 
spheres, whose rotational frequency depended on the number of attached magnetic bead 
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labels. [14, 15] Asynchronous magnetorotation was also used to measure the growth rate 
of attached bacteria, [16-18] and morphological changes of cancer cells. [19] 
 The beads used in this study are 1 μm Invitrogen™ Dynabeads. These beads, 
which exhibit superparamagnetic behavior, are composed of maghemite nanoparticles (γ-
Fe2O3), with a mean diameter of 8 nm, dispersed in a polystyrene matrix. [20] In the 
absence of a magnetic field, these beads exhibit no net magnetization, but within a 
magnetic field, the magnetic moments of the bead align with the field, making the beads 
magnetic.  
 It has previously been shown that within a two-dimensional rotating magnetic 
field, the dominant physical mechanism driving the rotation of the beads is the Neel 
relaxation of the γ-Fe2O3 nanoparticles embedded inside the bead. [14, 15, 21-23] At low 
driving field frequencies, the beads rotate in-phase with the driving field. At high driving 
field frequencies, the beads rotate out-of-phase, asynchronously, with the driving field. It 
is this asynchronous rotation, which depends on the physical properties of the beads, that 
allows for their rotation to be used to make biological measurements.  
 The use of surface-attached DNA molecules to control the assembly of micro- and 
nano-scale materials into highly-ordered crystalline structures has been shown before. 
[24-26] However, while those projects focused on the creation of single crystalline 
structures, the present project advances the concept one step further by focusing on the 
creation of structurally tunable assemblies, i.e. assemblies that can assume a variety of 
structures, depending on the protein concentration  
 The protein target used in this project is the blood coagulation factor thrombin, 
and the affinity molecules used are the well-studied thrombin aptamers. [27, 28] 
70 
 
Thrombin was chosen because of its popularity as an analyte in proof-of-principle 
studies, which facilitates evaluation of our method in the context of other methods. There 
are many papers demonstrating proof-of-principle work on signal transduction methods, 
all using the same thrombin aptamers in buffer, with reported limits of detection (LOD) 
ranging from 20 nM down to 6 fM. [29-48] To demonstrate the utility of our 
magnetorotation method, we studied the same biomarker, thrombin, using the same 
aptamers, and under similar conditions. Thus, while we intend to pursue biomarker 
detection in serum at a later time, here we limit our focus primarily to work on thrombin 
in buffer.  
 
Materials and Methods 
Materials 
  The magnetic beads used were 1 μm streptavidin-coated Dynabeads T1 MyOne 
beads (Invitrogen, Carlsbad, CA). The 1 μm beads used were selected after examining a 
wide range of beads, from 100 nm to 5 μm, optimizing parameters such as sedimentation 
rate, available binding sites, and magnetic volume. Human α-thrombin was purchased 
from Haematologic Technologies (Essex Junction, VT). Two anti-thrombin aptamers 
were used, the 15-mer  (5’-GGT TGG TGT GGT TGG) [27] and 29-mer  (5’-AGT CCG 
TGG TAG GGG CAG GTT GGG TGA CT) [28], with 20-base polyT tails, [34] and 
were synthesized with a 5’-biotinylation by Integrated DNA Technologies (Coralville, 
IA). Standard salts and Tween-20 were purchased from Sigma Aldrich (St. Louis, MO). 
Bovine serum albumin (BSA) 10% blocker solution was purchased from Thermo 
Scientific (Waltham, MA). Teflon-coated glass slides with 1 mm exposed glass spots 
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were purchased from Tekdon, Inc. (Myakka City, FL).  AS568-016 BN70 nitrile O-rings 
were purchased from Orings, Inc. (Los Angeles, CA). G661 general purpose lubricant 
was purchased from Novagard (Cleveland, OH).  
 A two-dimensional rotating magnetic field was constructed from orthogonal 
Helmholtz coils. The coils were built by 3D-printing a plastic mold consisting of four 
orthogonal rings, and wrapping coils of 22 gauge copper wire around the rings. Two 
sinusoidal waves, 90 degrees out-of-phase, were used to power the field and were 
generated within a LabVIEW program (National Instruments, Austin, TX), passed 
through a LabVIEW DAQ Board (NI USB-6211or NI SCB-68 connected to NI PCIe-
6321), amplified by a TX-PA40D two-channel amplifier (Radio Design Labs, Prescott, 
AZ), and then passed to the coils. The field had a frequency of 50 Hz and an amplitude of 
4 mT. The field rotated in a two-dimensional plane, which drove the rotation of the bead 
assemblies. The magnetic beads have a susceptibility (χ) of 8.1 x 10-4 m3/kg. [20] 
  Videos for magnetorotation analysis were captured on an Olympus IX71 inverted 
microscope (Olympus, Melville, NY) through a Basler piA640-210gm camera (Basler, 
Highland, IL). Videos were analyzed using the StAT Tracker [49] program written in 
LabVIEW and a MATLAB program, which is included in Appendix C-1. Higher 
resolution images for fractal analysis were captured on an Olympus BX50WI upright 
microscope through a Mightex BCE-B050-U camera (Mightex Systems, Toronto, 
Ontario, Canada). Images were analyzed using the FracLac plugin [50] for ImageJ 
(National Institutes of Health, Bethesda, MD).  
 For the laser-photodiode detection setup, a 650 nm, 20 mW laser module was 
purchased from Information Unlimited (Amherst, NH). FDS100 photodiodes were 
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purchased from ThorLabs (Newton, NJ). The components were secured using standard 
optic table equipment. Conditioning circuitry was built using standard electronics 
components. The conditioned signal was passed through the NI SCB-68 DAQ board and 
processed and analyzed in LabVIEW. 
 
Preparation of Bead Assemblies 
Wash buffer (1 M NaCl, 20 mM Tris, 1 mM EDTA, pH = 7.5), aptamer binding 
buffer (1 M NaCl, 5 mM Tris, 1 mM EDTA, pH = 7.5) and thrombin binding buffer (140 
nM NaCl, 50 mM Tris, 1 mM MgCl2, 10 mM KCl, 0.1% Tween-20, 0.1% BSA, pH = 
7.4) were prepared. [30, 34]  A 10 μL aliquot of the magnetic beads (10 mg/mL) was 
washed three times with the wash buffer, and then resuspended in 100 μL of aptamer 
binding buffer, and split into two portions. To each of the portions was added 3 μL of 50 
μM aptamer solution (either the 15-mer or the 29-mer), which represented a ten-fold 
molar excess, ensuring that the beads would be well functionalized with the aptamer, and 
they were incubated with gentle mixing for one hour. The biotinylated aptamers were 
attached to the streptavidin-coated beads via the biotin-streptavidin bond. The beads were 
washed three times with thrombin binding buffer, and resuspended at various 
concentrations (7 μg/mL, 22 μg/mL, 70 μg/mL, 220 μg/mL). Solutions of thrombin 
protein were diluted to various concentrations (ranging from 10 fM to 1 nM) with 
thrombin binding buffer. 100 μL of thrombin solution was mixed with 5 μL of a solution 
of 29-mer beads, incubated with gentle mixing for 10 minutes, followed by the addition 
of 5 μL of a solution of 15-mer beads at the same bead concentration. For control 
solutions, 100 μL of thrombin binding buffer, with no thrombin added, was used.  
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 Hanging droplets were prepared on a Teflon-coated slide, with an O-ring greased 
with lubricating grease in the middle (for sealing). Sixteen 1 μL droplets of thrombin-
bead solution were placed on the 1-mm exposed glass spots on the slide in a 4-by-4 array. 
The other side of the O-ring was greased, and a clear glass slide was placed on top, 
creating a seal around the droplets (this was to prevent evaporation as well as to minimize 
air currents disrupting the droplets). The slides were then inverted, so that the droplets 
hung down from the Teflon-coated slide. The slides were allowed to sit for 30 minutes, 
during which the beads fell through the solution, under the influence of gravity (bead 
density = 1.9 g/cm3). As the beads fell towards the tip of the droplet, if they encountered 
a thrombin molecule, the beads could bind to each other. In the absence of thrombin 
molecules, the beads collected in a tight cluster in the center of the droplet. The slides 
were then placed in the rotating magnetic field for magnetorotation and further analysis.  
 
Results and Discussion 
 A schematic showing the formation of the bead assemblies is shown in Figure 4.1 
After the beads are mixed in a microcentrifuge tube, and transferred to the hanging 
droplet, the beads fall to the bottom of the droplet, and form an assembly. In the absence 
of thrombin, there is nothing to bind the beads together, and they form a tight 
hexagonally-packed assembly, as shown in Figure 4.1d and in the image in Figure 4.1f. 
As the concentration of thrombin increases, the likelihood increases that an aptamer on 
the surface of one of the beads will bind to a thrombin molecule, and that it will 
encounter a second bead that has a free complementary aptamer on its surface, and that 
the thrombin molecule will bind to the second aptamer, linking the beads together. As the 
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concentration of thrombin increases, the number of beads that bind to each other 
increases. This results in a less-densely packed assembly of beads, one that has increased 
lacunarity (“gapiness”), and a decreased fractal dimension. At high thrombin 
concentrations, where each bead has many thrombin molecules bound to its surface, the 
conditions approach those of diffusion-limited aggregation: the bead density is relatively 
low, the primary means of transport is diffusion, and the beads bind instantly and 
irreversibly upon contact. [51] This results in the highly-branched bead assembly shown 
in Figure 4.1e, and in the image in Figure 4.1g.  
 
 
Figure 4.1—Schematic illustration of the bead assembly magnetorotation. (a), Beads 
coated with 29-mer thrombin aptamer are mixed with thrombin in a microcentrifuge tube, 
followed by addition of the 15-mer aptamer coated beads. (b) A 1 μL droplet of the bead 
solution is transferred to an inverted droplet. (c) The beads fall to the bottom of the 
droplet. A rotating magnetic field is then applied, to pull together beads which are not 
bound to thrombin. (d) In the case of no or low protein concentration, the beads assume a 
tightly-packed hexagonal arrangement. (e) In the case of high protein levels, the beads 
assume a highly branched structure. (f) A brightfield microscope image of hexagonally 
packed beads in the absence of protein. Imaged through a 40x water-immersion objective. 
Scale bar = 5 μm. (g) A brightfield microscope image of a loosely-packed bead assembly 
in the presence of high protein concentration. Imaged through a 40x water-immersion 





 The theory behind the rotation of microbeads composed of superparamagnetic 
nanoparticles has been discussed in depth elsewhere, [14, 15, 21-23] and will be 
summarized here. Briefly, we start with the equation for magnetic torque, = ×τ m B , 
where m is the magnetic moment of the bead, and B is the strength of the external 
magnetic field. Assuming steady state rotation, the rotational driving forces are equal in 
magnitude and opposite in direction to the viscous drag forces. Setting up a torque 
balance, the drag term can be expanded, τ /HV Tκη= , where κ is the shape factor, η is 
the fluid viscosity, VH is the hydrodynamic volume, and T is the rotational period. The 
rotational driving forces can be expanded with the following substitutions, 0µ=B H , 
where μ0 is the permeability of free space, H is the magnetizing field; mV=m M , where 
Vm is the volume of magnetic material, and M is the volumetric magnetic moment; 
χ=M H , where χ is the magnetic susceptibility of the bead; and ' ''iχ χ χ= − , where χ’ 
is the real component of the bead susceptibility, and χ’’ is the imaginary component of 
the bead susceptibility. We can combine all of these expressions to create an equation for 









=  (4.1) 
 
This equation can be expressed in terms of experimentally measurable parameters by 
making further substitutions: ( ) ( )2 20'' / 1N Nχ χ τ τ= Ω +Ω , where χ0 is the DC bead 
susceptibility, Ω is the frequency of the driving field, and τN is the Neel relaxation time; 
( ) ( ){ }exp /N p B KKV k Tτ = , where K is the magnetic anisotropy constant, Vp is the volume 
76 
 
of the magnetic nanoparticles, kB is Boltzmann’s constant and TK is the ambient 
temperature.  
 With our experimental setup, it’s possible to hold most of the terms in equation 
(4.1) constant. Assuming that all of the bead aggregates have a circular shape, κ is held 
constant. Assuming that all aggregates are formed with the same number of beads, Vm is 
constant, and assuming that all the beads have similar material properties, χ’’ is constant. 
Holding H and η constant across all experiments is simple. That leaves only VH as a 
variable that can change among experiments, so equation (4.1) can be simplified to: 
 
 HT V∝  (4.2) 
 
Therefore, the rotational period of the self-assembled aggregate varies only with its 
hydrodynamic volume.  
Bead assemblies were prepared using four different bead concentrations: 7 
μg/mL, 22 μg/mL, 70 μg/mL and 220 μg/mL, which enabled an increased overall 
dynamic range. Figure 4.2 shows a series of images of bead assemblies produced with a 
bead concentration of 220 μg/mL, illustrating the effects of thrombin concentration on the 
size, shape, fractal dimension and lacunarity of the bead assemblies. Additional images, 






Figure 4.2—A series of brightfield microscope images illustrating the effects of protein 
concentration on the shape, lacunarity and fractal dimension of the bead assemblies. 
Initial bead concentration was 220 μg/mL. The fractal dimension for each bead assembly 
is provided. Left column was taken using a 20x water-immersion objective, right column 
was taken using a 40x- water-immersion objective. Scale bar = 20 μm.
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Figure 4.3—A series of brightfield microscope images illustrating the effects of protein 
concentration on the shape, lacunarity and fractal dimension of the resulting bead 
clusters. Initial bead concentration was 70 μg/mL (left 2 columns) and 22 μg/mL (right 2 




Rotational Period Dose Response Curves 
Figure 4.4 shows a series of dose-response curves for the magnetorotation of the 
bead assemblies at the four different bead concentrations. The data is normalized over the 
range of 1-10 seconds to facilitate comparison between the different bead concentrations 
(the non-normalized data, shown in Figure 4.5, ranges from 1-15 seconds). The data was 
normalized through the logistic Hill equation that fit the data. After the original data was 
fit with the Hill equation, for the parameters of the Hill equation, the data was normalized 
by setting the rotational period at zero concentration to 1 s/s, and the rotational period at 
infinite concentration to 10 s/s, and creating a linear relationship to scale the original 
logistic fit to the normalized logistic fit. This relationship was then applied to the data.  
The dynamic range shifts to the right and limit of detection (LOD) increases as the 
concentration of beads increases. This is because the dynamic range and LOD depend on 
the ratio of thrombin molecules per bead (this is discussed in further detail below and in 
Table 4.1). Based on the average number of thrombin molecules and beads in solution at 
the LOD, and the energy of the thrombin-aptamer bond, it seems possible that only a 
single thrombin molecule is needed to bind any two beads together, as a step in the 
formation of a bead assembly, in the hanging droplet. Each data point on the graph 
represents the average of ten bead assemblies (± SD). The coefficient of variation 
decreases with increasing bead concentration, because a larger number of beads increases 
the uniformity of the assemblies.  
The LOD for each bead concentration, as shown in Figure 4.4b, is calculated 
based on the average rotational period of the control plus three standard deviations, and 
then determining the concentration that corresponds with that period along the logistic 
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curve that fits the data. [52] The data is fit with the logistic Hill equation. [53] The LOD 
of the lowest bead concentration, 7 μg/mL, is 80 fM, which is among the lowest LODs 
reported for a thrombin-based diagnostic system in buffer [29-48, 54]. Of these papers, 
only three [34, 39, 40] report quantitative results measured in whole or diluted serum, all 
of which show much higher limits of detection than in buffer. We believe that these 
observations reflect the challenges associated with using the specific thrombin aptamers 
in a complex matrix, such as serum. This issue is discussed in greater detail in Chapter 5.  
 
Figure 4.4—(a) Dose-response curves for the normalized rotational period of bead 
assemblies from 4 bead concentrations, 7 μg/mL, 22 μg/mL, 70 μg/mL and 220 μg/mL. 
The curves are fit with the logistic Hill equation. The rotational periods of the bead 
assemblies were normalized, based on the Hill equation fit through each point, such that 
the curve had a minimum value of 1 s/s and a maximum value of 10 s/s. This was done to 
make it easier to compare the behaviors of the different curves. Each point represents the 
average of the rotational period of ten bead assemblies, and the error bars are ± SD. (b) A 
table showing the limit of detection (LOD) for each bead concentration, as well as the 
normalized rotational periods of the control bead assemblies (no thrombin) for each bead 




Figure 4.5— (a) Rotational period of self-assembled microbead aggregates with different 
microbead concentrations and different thrombin concentrations.  Each point represents 
the mean ± SD of 10 aggregates. Each data set was fit with the logistic Hill equation. (b) 
Limit of detection and control values corresponding to the data shown in (a). The limit of 
detection was calculated as the mean control value ± 3 SD.   
 
Calculation of Binding Site Occupation on the Beads 
 The following calculations will show how we’ve calculated the number of 
thrombin molecules that are bound to each bead. The 29-mer beads are first mixed with 
the thrombin. These beads have a reported binding capacity of 400 pmol biotin/mg beads, 
[55] which is enough to bind all the thrombin present in our solutions (see Table 4.1). 
Based on the reported bead density of 1.9 g/mL, [55] each bead has a mass of 
approximately 10-9 mg, which means that each bead can bind approximately 240,000 
biotinylated molecules. Solutions are prepared by mixing 4.8 μL of the 29-mer beads (it 
is the concentration of this solution on which we base on determination of bead 
concentration, e.g., 220 μg/mL) with 100 μL of thrombin solution, followed by the 
subsequent addition of 4.8 μL of the 15-mer beads. This produces a solution with final 
volume of 109.6 μL, from which the 1 μL droplets are produced. Based on these 
numbers, we calculated the average number of thrombin molecules per bead, assuming 
that all thrombin molecules were bound, and that they were uniformly distributed across 
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all the beads. The calculations of the number of thrombin molecules per bead, and the 
percentage of the available binding sites that are occupied per bead, for the bead 








































7 0.08 10 306 143 0.060% 17900 7.44% 
22 0.195 30 962 111 0.046% 17000 7.10% 
70 1.06 100 3060 189 0.079% 17900 7.44% 
220 5.3 300 9620 301 0.125% 17000 7.10% 
Table 4.1—The average number of thrombin molecules and percentage of binding sites 
occupied per bead at the limit of detection (LOD), the point at which the effects of the 
thrombin molecules on the shape of the bead aggregate are first detectable by 
magnetorotation, and at the top of the dynamic range, the point at which the dose-
response curve plateaus, and any additional thrombin molecules will not have a 
significant effect on the shape of the bead aggregate. The LOD values correspond with 
those shown in Figure 4.4b. The top of the dynamic range is estimated from the curve. 
The initial bead concentration refers to the initial concentration of both the 15-mer and 
29-mer beads before they are added to the thrombin solution. The beads per droplet, 
thrombin molecules per bead and percent binding sites occupied represent average 
expected values based on the parameters provided above.  
 
 Additionally, assuming that the streptavidin-aptamer-thrombin-aptamer-
streptavidin binding complex has a total length of around 20 nm, steric hindrances would 
only allow a fairly small amount of the surface area of each bead to participate in 
binding. Assuming that two beads bind “pole-to-pole” only the surface of the bead within 
a 10 nm of the pole height would be capable of participating in the binding event. By 
using the equation for calculating the partial surface area of a sphere, 2 sinA r d dθ θ φ= ∫∫ , 
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only about 1% of the bead’s surface area can participate in binding to another bead. 
Given that, at the LOD, each bead likely has between 100-300 thrombin molecules on its 
surface, and only 1% of the bead’s surface participates in the binding event, it is likely 
that only a few thrombin molecules are needed for binding two beads together.  
 
Calculation of Energies of Bond Strengths and Rupture Forces 
The energy of the bond between thrombin and the 15-mer aptamer, which is the 
weaker of the two aptamers, has been reported as 44.5 kBT. [56] For the effects of gravity 
on two beads bound together, it was assumed that one bead would be held stationary 
while the second would be free to rotate around it due to gravity. Using the equation for 
work due to rotational torque, W φ= ×r F , where r is the vector of the lever arm (in this 
case with the magnitude of one bead diameter, 1 μm), F is the force of gravity on the 
bead, and φ is the angle through which the work occurs (assuming a full 180 degree 
rotation), the work performed comes out to about 7.6 kBT, which is less than the bond  





= , where m is the bead mass, g is the gravitational acceleration, η is 
the solution viscosity and r is the bead radius. With a kinetic energy of 
2
2
mvE = , one 
bead has a kinetic energy << 1 kBT. 
 
Fractal Dimension and Lacunarity Dose Response Curves 
Figure 4.6 shows the fractal dimension and lacunarity (the measure of gappiness 
of a structure) of the bead assemblies for three different bead concentrations, 22 μg/mL, 
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70 μg/mL and 220 μg/mL, (7 μg/mL assemblies were too small to accurately quantify 
using this method) as measured by the ImageJ plugin FracLac. [50] The fractal dimension 
of a solid two-dimensional object is 2, and the fractal dimension of a diffusion-limited 
aggregate is approximately 1.71. [51] Figure 4.6a suggests that at high thrombin 
concentrations, the bead assemblies might have a structure similar to that of diffusion 
limited aggregates. Figure 4.6c shows the relationship between fractal dimension, 
lacunarity, and the normalized rotational period, for the 22 μg/mL bead assemblies.  
There are two primary advantages that the rotational period analysis has over 
image analysis (fractal dimension and lacunarity) as a method for measuring the protein 
concentration. The first is that assemblies from the lowest bead concentration (7 μg/mL) 
could not be accurately measured by image analysis, because the relatively small number 
of beads in the assembly results in an unacceptably high level of fluctuations/noise in the 
measured values, which is not the case with the rotational period measurements. 
Therefore, analysis by the rotational period method allows for greater sensitivity and 
dynamic range. The second advantage is that the rotational period can be measured using 
just a portable laser-and-photodiode setup (discussed below), in contrast to the 
microscope required for image analysis, which would allow for a portable, rugged and 
inexpensive instrument for decentralized (“in the field”) measurement locations. 
Additionally, it should be noted that magnetorotation is still required for performing 
image analysis. The rotating magnetic field is needed to pack the beads into the dense 
hexagonal configuration, without which the fractal dimension and  lacunarity  cannot be 
accurately measured at low protein concentration (without the field, the beads will diffuse 
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away from the center of the assembly via Brownian motion, creating the appearance of 
higher lacunarity and lower fractal dimension).  
 
Figure 4.6—(a) Fractal dimension, and (b) Lacunarity of bead assemblies. Three bead 
concentrations are shown, 22 μg/mL, 70 μg/mL and 220 μg/mL. For both plots, each 
point represents an average over ten bead assemblies; error bars are ±SD. Curve is the 
logistic Hill equation [57] fit to the data. (c) The relationship between rotational period, 




The data in Figure 4.6b suggest that among image analysis methods, for the data 
presented here, the fractal dimension appears to provide more useful information than the 
lacunarity. We included the lacunarity to show that it could also be used as a method for 
measuring protein concentration through bead assembly. We examined additional image 
analysis methods; including measuring the physical size of the assembly via the radius of 
gyration of the assembly and measuring the angles between adjacent nearest-neighbor 
beads, (see Appendix B) but those methods did not provide as much information as 
fractal dimension and lacunarity.  
 
Laser and Photodiode Setup  
 In order to facilitate the performance of BAM without the use of a microscope, it 
would be necessary to develop a simple, inexpensive and portable detection apparatus. To 
this effect, we designed a laser-and-photodiode detection apparatus from inexpensive, 
readily available laboratory components, as shown in Figure 4.7a. When a low power (20 
mW, 650 nm) laser diode is shined on a droplet containing a bead assembly, the droplet 
acts as a lens, focusing the beam through its center, where the assembly lies. This creates 
a projection of the bead assembly that is magnified by beam spreading caused by the 
droplet focusing (in practice, a bead assembly that is approximately 100 μm in diameter 
is magnified to approximately 4-5 cm over a distance of approximately 20 cm). This 
rotation of the projection of the bead assembly is captured by a 3-by-3 array of 
photodiodes located underneath the droplet. The signals from each of the photodiodes are 
recorded in LabVIEW, and analyzed with a Fourier transform to determine the rotational 
period of the assembly (a screenshot of this program is shown in Figure 4.8 below). 
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Having multiple redundant signals (each of the nine diodes calculates the rotational 
period independently, creating a set of redundant signals) helps to increase confidence in 
the output.  
 
 
Figure 4.7—(a) A schematic of the laser-and-photodiode setup. A low-power red laser is 
aimed at the center of the droplet holding the self-assembled aggregate. The droplet 
optically focuses the beam through the aggregate, creating a projection of the rotating 
aggregate onto an array of photodiodes. The periodic signal captured by the photodiodes 
is analyzed by a computer program, from which it calculates the rotational period using a 
Fourier transform. (b) Rotational period of bead assemblies as captured by the 
microscope (blue, left axis) and the laser-photodiode setup (red, right axis). Each point 
represents the mean ± SD of 10 assemblies. Both data sets were fit with the logistic Hill 
equation. 
 
The performance of the laser-and-photodiode apparatus was validated by 
measuring the magnetorotation of a series of 220 μg/mL bead assemblies on the 
microscope and then on the laser-and-photodiode apparatus, as shown in Figure 4.7b. The 
difference in the relative values of the rotational periods between the two systems is due 
to differences in the strengths of the magnetic field (4 mT on the microscope, 4.7 mT on 
the laser-photodiode setup) on the two setups. However, the shapes of the two curves 
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closely follow each other, suggesting that a simple, inexpensive laser-and-photodiode 
system is capable of measuring the magnetorotation, and therefore the thrombin 
concentration, of magnetic bead assemblies without the use of a microscope.  
 
 
Figure 4.8—Above is a screenshot of the LabVIEW program to collect and analyze the 
data captured by the photodiodes of the rotating projecting of the bead assembly. Traces 
from all nine diodes are shown (each trace is 10 seconds of data). Due to limitations of 
the computer that was used to perform the experiment, only three Fourier transforms 
could be performed simultaneously in real-time without slowing down the data collection 
process. In this screenshot, diodes 1, 2 and 4 are selected, each outputting a rotational 






 This chapter introduces Bead Assembly Magnetorotation as a viable signal 
transduction method for measuring the concentration of a protein in solution through two 
different methods, magnetorotation and fractal analysis. The 80 fM LOD of this system 
for the protein thrombin is very competitive with existing detection methods. The simple 
laser-and-photodiode portable detection setup represents a potential for the development 
of BAM into a point-of-care detection system. In future work, we intend to demonstrate 
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The Performance of BAM in Serum with the Thrombin Aptamers 
 
Introduction 
 As detailed in the previous chapter, in buffer, BAM showed a very low limit of 
detection (LOD) (80 fM), a short analysis time, and the ability to be performed on a 
microscope-free laser-and-photodiode setup. However, in order for BAM to become a 
clinically relevant technology, there is one final step that must be attained, the 
performance of BAM in serum. The performance of a diagnostic assay in serum is 
challenging because of nonspecific binding between the serum proteins and the affinity 
molecules and the surfaces of the diagnostic assay. [1] Given the much greater 
concentration of serum proteins (on the order of millimolar) relative to the target protein 
(on the order of picomolar or lower), nonspecific interference from serum proteins can 
result in substantially degraded system performance.  
 One of the most popular molecules used to mitigate nonspecific binding from 
serum proteins is poly(ethylene glycol) (PEG). [1, 2] PEG is a fairly simple molecule: 
HO—(CH2CH2O)n—CH2CH2OH 
with n representing the number of repeats of the ethylene glycol subunit. PEG is an 
incredibly hygroscopic molecule, capable of adsorbing several times its own weight in 
water molecules via hydrogen bonding. [3] For these reasons, PEG has been a very 
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popular molecule for use in preventing biofouling on the surfaces of biological devices. 
[4-6] In the absence of any molecule used to mitigate nonspecific serum interactions with 
the beads, large amounts of these nonspecific interactions will significantly diminish the 
system. This chapter will discuss attempts to use PEG to mitigate the nonspecific serum 
interactions, to allow BAM to be performed in serum.  
 
Materials and Methods 
 The experiments in this chapter used heterobifunctional PEG, with one end of the 
molecule functionalized with biotin, and the other end functionalized with maleimide, as 
shown in Figure 5.1 below. (The use of homobiofunctional PEG results in crosslinking of 
the beads.) This will allow for one end of the molecule to be attached to the beads via 
biotin-streptavidin conjugation, and the other end of the molecule to be attached to the 
aptamer via maleimide-thiol conjugation. Two different molecular weight PEG sizes 
were used: 2000 Da (2K) and 10,000 Da (10K), purchased from Creative PEG Works 
(Winston-Salem, NC).  
 
Figure 5.1—Schematic illustration of the biotin-PEG-maleimide heterobifunctional PEG 
used in this experiment. [7] 
 
 The following procedure was adapted from Bioconjugate Techniques. [8] A 10 μL 
aliquot of Invitrogen Dynal MyOne Streptavidin T1 beads (10 mg/mL) was taken and 
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washed three times and resuspended in 100 μL of a 20 mM Na2HPO4, 150 mM NaCl, 
pH=7.4 buffer. The binding capacity of this aliquot of beads is 40 pmol. A ten-fold 
excess of PEG (4 μg for the 10K PEG, 0.8 μg for the 2K PEG) was dissolved in buffer at 
5 mg/mL, and 1 μL of solution was added to the beads solution. The solution was then 
placed on the end-over-end rotator for 30 minutes. 
 Dithiolated aptamers (the 15-mer and 29-mer) both with and without a 20-base 5’ 
polyT tail were purchased from IDT (Coralville, IA). The dithiol groups were reduced to 
thiol groups using tris(2-carboxyethyl)phosphine (TCEP) by the following procedure. A 
boiling water bath was prepared. The TCEP was diluted from the 0.5 M stock to 200 μM 
with buffer. A 2 μL aliquot of each thiolated aptamer (50 nmol/mL) was mixed with 5 μL 
of 200 μM TCEP, covered with parafilm, and then submerged in the boiling water bath 
for 5 minutes. In the meantime, the beads which had been incubated with the PEG were 
washed with buffer, resuspended in 100 μL of buffer and split into two 50 μL aliquots 
(one for each aptamer). The aptamer solution was then quickly transferred to the beads, 
because the thiol and maleimide groups are highly reactive. The solutions were then 
incubated with end-over-end rotation for 2 hours, after which they were washed again 
and resuspended at their final desired concentration.  
 Off-the-clot human serum was purchased from PAA Laboratories (Dartmouth, 
MA). Human α-thrombin was purchased from Haematologic Technologies (Essex 
Junction, VT). Various concentrations of beads, thrombin, and serum were prepared, and 
then transferred to hanging droplets. Hanging droplets were prepared on a Teflon-coated 
slide, with a greased O-ring in the middle (for sealing). Sixteen 1 μL droplets of 
thrombin-bead solution were placed on the 1.5-mm exposed glass spots on the slide in a 
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4-by-4 array. The other side of the O-ring was greased, and a clear glass slide was placed 
on top, creating a seal around the droplets (this was to prevent evaporation as well as to 
minimize air currents disrupting the droplets). The slides were then flipped over, so that 
the droplets hung down from the Teflon-coated slide. The slides were allowed to sit for 
30 minutes, during which the beads fell through the solution, under the influence of 
gravity (bead density = 1.9 g/cm3). As the beads collected in the tip of the droplet, if they 
encountered a thrombin molecule, the beads could bind to each other. In the absence of 
thrombin molecules, the beads collected in a tight cluster in the center of the droplet. The 
slides were then placed in the rotating magnetic field for magnetorotation and further 
analysis.  
 
Results and Discussion 
 Experiments were performed to examine the effects of the PEG coating on the 
formation of bead clusters without the presence of thrombin. Three groups of beads were 
prepared: beads coated with 10K PEG, but without aptamers; beads coated with 
aptamers, but without PEG (effectively the control group); and beads coated with both 
10K PEG and aptamers. No thrombin was included. Five different dilutions of serum 
were prepared: 10% serum, 1% serum, 0.1% serum, 0.01% serum, and a buffer control. 
Bead solutions with a concentration of 70 μg/mL were prepared with each of the serum 









































   
Figure 5.2—A series of images showing magnetic bead assemblies prepared with 10K 
PEG-coated, aptamer-coated, and 10K PEG+aptamer-coated beads, in 10%, 1%, 0.1%, 
0.01% serum and a buffer control. 
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 Since there was no thrombin present in these samples, the expectation was to see 
a tight hexagonally-packed cluster in each image; any deviation from this would indicate 
the presence of nonspecific binding. In the first column, the PEG-only beads, tightly-
packed clusters can be found in the 1%, 0.1%, 0.01% serum and control (0%) samples. In 
the 10% serum sample, however, there does appear to be some nonspecific binding. As 
an additional test to confirm these observations, which were produced under a rotating 
magnetic field, the field was turned off, and then the cluster was monitored for the 
presence of Brownian motion of the beads diffusing away from the center of cluster. In 
the absence of a molecule to bind the beads together, the beads begin to slowly diffuse 
away from the center of the cluster due to Brownian forces. In the case of the 10% serum, 
no such diffusion was observed, confirming the fact that the serum was nonspecifically 
binding to the surface of the bead.  
 In the case of the aptamer-only beads, nonspecific binding was observed in all 
serum samples. The buffer control showed no nonspecific binding. In the case of the 
beads coated with both PEG and aptamer, nonspecific binding was observed in all of the 
serum solutions except for the 0.01% serum solution, as well as for the control. This was 
confirmed by checking each sample for the presence of Brownian diffusion of the beads 
after turning off the magnetic field.  
 This experiment revealed several interesting facts about the nonspecific binding 
of serum proteins. The serum proteins appear to bind to both the bead as well as to the 
aptamer itself. The binding of serum proteins to the bead can be mitigated by PEG, but 
the binding to the aptamer is much harder to mitigate. In the case of the PEG-only beads, 
the PEG effectively mitigated serum nonspecific binding at only a 100-fold dilution of 
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the serum (100% to 1%). With the addition of the aptamer to the PEG, another 100-fold 
dilution of the serum (1% to 0.01%) was needed again to mitigate the nonspecific binding 
effects of the serum. These results would suggest that in order to use these beads in 
serum, a 10,000-fold dilution of the sample would be necessary. The primary conclusions 
that can be drawn from this experiment are that, while PEG can mitigate nonspecific 
interactions, it does not provide a perfect solution, and that the nonspecific binding of the 
serum proteins to the aptamer is a significant factor that must be taken into consideration.  
 We next attempted to see if washing the beads could assist in mitigating the 
nonspecific binding of the serum proteins. Solutions of beads were prepared with four 
different concentrations of serum, 10%, 1%, 0.1% and 0.01%, as in the previous 
experiment, but before transferring the solution to inverted droplets, the solution of beads 
was washed two times by using a magnetic separator to pull the beads to the side of the 
tube, removing the remaining solution, and resuspending the beads in fresh buffer. The 
results from this experiment are shown in Figure 5.3 below. These results show that with 
2 washing steps, there was no nonspecific binding in the 0.1% or 0.01% serum solutions, 
but that there was nonspecific binding in the 10% and 1% serum solutions. This 
represents a ten-fold improvement over the case with no washes, in which nonspecific 
binding was detected in all but the 0.01% serum solution. These results suggest that 
washing the beads two times by magnetic separation can remove some of the serum that 
binds nonspecifically to the beads.  
The second step of this experiment, however, was to examine the effects of 
washing on the binding of thrombin to the beads. Solutions of bead assemblies were 
prepared with four different thrombin concentrations, 1 nM, 100 pM, 10 pM, and 1 pM , 
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and a thrombin-free buffer control. One set of solutions was prepared in 0.01% serum, 
and the other was prepared in 0.1% serum. The samples prepared in 0.01% serum were 
not washed, and the samples prepared in the 0.1% serum were washed twice. Images are 
shown in Figure 5.4 below. 
In the left-hand column of Figure 5.4, with the bead assemblies prepared with 
thrombin in 0.1% serum with two washes, there was no binding detected in any of the 
bead assemblies. This indicates that the magnetic washing step likely removes all of the 
bound thrombin. In the control sample, the 0.01% serum with no washing, binding can be 
detected in the 10 pM, 100pM and 1 nM samples. The results of this experiment show 
that in addition to removing nonspecifically bound serum proteins, washing of the beads 
before the formation of droplets likely removes any bound thrombin from the bead. 
Based on the data shown in Figures 5.2, 5.3 and 5.4, the conclusion was reached that, due 
to the effects of serum proteins binding to both the beads and the aptamer, a 10,000-fold 
dilution must be performed in order to perform BAM in serum with this aptamer/bead 











































Figure 5.3—Beads coated with 10K PEG and the aptamers in different serum 
concentrations. The beads in the column on the left were washed twice by magnetic 
separation, and the beads in the column on the right were not washed. 
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Figure 5.4—Examination of the effect of washing on formation of bead assemblies with 
thrombin.  Thrombin concentration is listed on the left hand side. The left column is in 
0.1% serum with 2 washes, the right column in 0.01% serum with no washes. 
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Dose-Response Curves in Serum 
 With these results in mind, we attempted to produce dose-response curves for 
BAM in serum, similar to those shown in the previous chapter. Two different bead 
concentrations were used, 22 μg/mL, and 70 μg/mL, corresponding with the two middle 
concentrations shown in Figure 4.3. In order to simulate a real clinical sample, various 
concentrations of thrombin were spiked into whole human serum, which was then diluted 
10,000 times with buffer, as discussed earlier in this chapter. The inverted droplets were 
prepared as detailed in the Materials and Methods section of this chapter. For each 
sample, videos of ten bead assemblies were recorded and analyzed. The dose response 
curves for these two bead concentrations are shown in Figure 5.5 below. The thrombin 
concentrations shown in Figure 5.5 are based on the concentration of thrombin that was 
spiked into whole serum, which was then diluted 10,000 times with buffer (e.g., 1 nM in 
whole serum is equivalent to 100 fM in 0.01% serum). The magnetic driving field had an 
amplitude of 4 mT and a frequency of 50 Hz. The video capture program recorded videos 
at 40 frames per second.  
These dose response curves demonstrate that, while BAM does produce a result in 
diluted serum, the quality of the data is not very good. The coefficient of variation of 
each data point is higher than in the buffer case, and the vertical resolution is significantly 
poorer. The LOD for the 22 μg/mL bead concentration is 16 nM, and the LOD for the 70 
μg/mL bead concentration is 7.5 nM. Based on the results shown in Chapter 4, the LOD 
for the 22 μg/mL bead concentration would have been expected to be lower than that of 
the 70 μg/mL bead concentration. This discrepancy is likely due to the increased noise 
generated by the serum. Comparing the LODs to those reported for the same bead 
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concentrations in buffer in Chapter 4, for the 22 μg/mL bead concentration (0.195 pM 
LOD in buffer), the serum LOD is 82,000 times higher, and for the 70 μg/mL bead 
concentration (1.05 pM LOD in buffer), the serum LOD is 7,100 times higher. Based on 
the dilution required to mitigate the interference of serum on the beads, we would have 
expected the LOD to increase by a factor of 10,000. 
 
Figure 5.5—Dose response curves with (a) 22 μg/mL bead concentrations and (b) 70 
μg/mL bead concentrations for bead assembly magnetorotation in whole serum spiked 
with human thrombin. Each point on the graph represents the average (± standard 
deviation) rotational period of ten bead assemblies, as calculated from videos of their 
rotation. The points were fit with the logistic Hill equation. The LOD for the curves, 
based on the mean ± 3 SD of the control, are (a) 16 nM, and (b) 7.5 nM. Note: The given 
concentrations of thrombin are before dilution; the actual concentrations after the dilution 
are 10,000x lower. 
  
Partial Collapse of the Assemblies 
 In addition to serum nonspecific binding, one of the primary causes for the 
significantly poorer performance of BAM in serum was the partial inward collapse of the 
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The formation of the bead assembly, before the magnetic field was turned on, occurred as 
expected, with the beads collecting at the bottom of the droplet binding to each other, and 
then forming an assembly. However, once the magnetic field was turned on, the 
assemblies began to partially collapse inwards, i.e. collapse on themselves. This effect 
never occurred when BAM was performed with the beads coated only with the aptamers 
(and not PEG). When the beads were not PEGylated, as soon as the field was turned on, 
the assemblies locked into place, and began rotating, without any detectable collapse or 
change in the shape of the assembly.  
The collapse of the assemblies with PEGylated beads occurred in both buffer and 
serum. It occurred with both 10K PEG and 2K PEG, as well as with aptamers both with 
and without the 20-base polyT tail. I believe that this is due to the lack of rigidity of the 
PEG molecule relative to the aptamer. The aptamer is a fairly bulky and rigid molecule, 
with plenty of intramolecular binding (e.g. GC-rich regions, complementary strands), 
double bonds, and intramolecular repulsions to stabilize it. The PEG molecule, however, 
is very flexible, being very hygroscopic, and containing no double bonds. I believe that 
the inclusion of the PEG molecule, even one as small as 2K (the smallest commercially 
available heterobifunctional PEG molecule), into the bead-bead linker significantly 
reduces its rigidity. When the field is turned on, the beads become magnetized, and 
attracted to each other, which creates a net force pulling towards the center of the 
assembly. Without the PEG molecule, the bead-bead linker is rigid enough to resist this 
inward pull. However, with the inclusion of the PEG molecule, the linker is no longer 
rigid enough to resist the inward force, leading to the assembly’s partial inward collapse. 
A series of images showing this effect are given below in Figure 5.6.  
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Figure 5.6—A series of figures illustrating the collapse of bead assemblies after turning 
on the rotating magnetic field. The top row of images shows beads functionalized with 
2K PEG and short  aptamers (with no 20-base polyT tail). The bottom row of images 
shows bead functionalized with 10K PEG and aptamers with a 20-base polyT tail. 
 
 Based on the results shown in Figures 5.5 and 5.6, it appears that BAM has the 
potential to work in serum; however, a much more rigid molecule that repels the 
nonspecific interactions of serum molecules with the bead would need to be found.  
 An additional method that was explored to potentially mitigate serum interactions 
was the use of nonspecific aptamer competitors, a concept that was used successfully in 
the work described in Chapter 6. The idea is that since the serum proteins stick to many 
biomolecules, they would just as likely bind to a random oligonucleotide sequence as to 
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our aptamer. Therefore, if a large excess of a random oligonucleotide sequence, on the 
order of the concentration of serum proteins in solution, was introduced into the serum, 
the serum proteins would bind to this nonspecific sequence, and not to our aptamer or our 
bead. The problem with this approach is that the thrombin aptamers are so sticky, that 
they bound to all of the nonspecific aptamer sequences that we tried to use. The aptamer 
used in Chapter 6 was designed for diagnostic applications, and therefore was less sticky, 
making the nonspecific aptamer strategy successful. 
 
Evaluation of our Results in Context  
 One of the advantages of working with the thrombin aptamers is that their 
popularity makes it easy to compare the sensitivity of various diagnostic methods. Table 
5.1 shows the results of a survey of the literature for proof-of-principle work for novel 
signal transduction mechanisms using the (same) thrombin aptamers, with results both in 
buffer as well as in serum. 
In light of the results shown in Table 5.1, BAM compares pretty favorably  to 
existing methods. In buffer, BAM has an LOD lower than all but one of the methods, and 
that one involved a multi-step amplified procedure that takes over 24 hours. I think it is 
particularly interesting that only three papers show quantitative results in serum. 
Additionally, those three reported LODs in serum are very close to each other, and very 
close to the results that I obtained during my experiments (Figure 5.5). I believe that this 
reflects the challenges associated with using the thrombin aptamers in serum. Based on 
these data, it seems like these aptamers have a relatively high affinity for serum proteins, 
which is an inherent limitation of the aptamers, and would be extremely difficult to 
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counteract without changing their structure. It seems like during the development of 
aptamers for application in diagnostic devices, it would be beneficial to test for their 
affinity towards nonspecific competitors such as serum proteins.  It also seems like the 
thrombin aptamers are not well suited for use in proof of principle demonstrations of 
signal transduction methods in serum. 
Paper Signal Transduction Method LOD Buffer 
LOD 
Serum 
Pavlov, JACS, 2004 [9] Aggregation of Nanoparticles 20 nM  
Huang, Anal Chem, 2004 [10] Capillary electrophoresis 9.8 nM  
Hianik, BMCL, 2005 [11] Quartz crystal microbalance 1 nM * 
Liu, ACS Nano, 2012 [12] Fluorescence 1 nM  
Radi, JACS, 2006 [13] Fluorescent molecule beacons 500 pM  
Tennico, Anal Chem, 2010 [14] Quantum Dots 500 pM  
Centi, Anal Chem, 2007 [15] Electrochemical 450 pM 5 nM 
Kim, Nanotechnology, 2009 [16] Si-nanowire FET 330 pM * 
Cai, Sensors and Actuators, 2006 [17] Electrochemical 100 pM  
Zhou, Anal Chem, 2012 [18] SPR-phase imaging 100 pM  
Cho, Nano Letters, 2008 [19] Raman scattering 100 pM 10 nM 
Song, Chromatography, 2009 [20] Capillary electrophoresis 83 pM 3 nM 
Hu, JACS, 2012 [21] Electrochemical 50 pM  
Bai, Biomaterials, 2012 [22] Electrochemical (graphene-enhanced) 11 pM  
Ho, JACS, 2004 [23] Label-free fluorescence 10 pM  
An, Lab Chip, 2010 [24] SWNT Cantilevers 7 pM  
Li, Anal Chem, 2007 [25] Enzymatically Amplified SPR 500 fM  
Hansen, JACS, 2006 [26] Electrochemical breakdown of QD 500 fM  
Rahman, Anal Chem, 2009 [27] Au-NP-Ferrocene Electrochemical 140 fM * 
Zhang, Biosensors Bioelec, 2009 [28] NP-Amplified electrochemical (24 hr+) 6 fM  
Table 5.1—A survey of the literature showing the LODs in buffer and serum of 20 
different systems using the thrombin aptamers as signal transduction molecules for the 
proof-of-principle demonstration of a new signal transduction method. Entries marked 
with an asterisk (*) indicate that the authors discussed that the method was performed in 
serum, but do not show any detailed data or report an LOD in serum. For paper [19], the 
LOD was reported as 1 nM in 10% diluted serum. For paper [20], the LOD was reported 
as 55 nM in 2% serum. Those values were adjusted to represent the LOD in whole serum, 
to enable a fair comparison.  
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 In addition to comparing our system against other signal transduction methods 
that use the thrombin aptamers, we wanted to compare the performance specifications of 
our BAM system against those of what are generally considered to be the two leading 
research groups in the field of magnetic particle-based diagnostics, the Shan Wang group 
from Stanford University, and the Ralph Weissleder group from Harvard University. The 
Wang group uses giant magnetoresistance (GMR) as their signal transduction method, 
and the Weissleder group uses magnetic relaxation (MR) as their signal transduction 
method. As described in greater detail in Chapter 1, GMR operates by measuring the 
change in potential across a sensor surface due to the proximity of sandwich-label 
magnetic particles. MR operates by measuring the change in the relaxation time of 
magnetic nanoparticles due to their target-induced clustering.  Both groups are far more 
advanced in the development of their system then we are, with working prototypes that, 
as of this writing, are undergoing commercial development and testing. Our system is 
still in the initial prototype stage, where I believe there is much room for improvement in 
many areas of the device. A summary of the comparison between the three systems is 
shown in Table 5.2 below.  
All three systems are small enough to be portable, approximately what can be 
termed “hand-held.” The smallest system is the Wang GMR, which measures 
approximately 8 x 16 x 3 cm. [29] The Weissleder MR system is slightly bigger, at 20 x 
12 x 5 cm, [32] while our system is a little bigger still at approximately 15 x 15 x 50 cm. 
In terms of analysis time, the systems are all fairly similar; the Wang GMR has an 
analysis time of 20 minutes, [29] the Weissleder MR 30 minutes, [32] and our system 40 
minutes. The sample volume required for analysis is also all fairly similar, in that the 
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volumes are on the order of a drop of blood; the Wang GMR has a sample volume of 50 
μL, [29] the Weissleder MR 5 μL, [34] and our system 100 μL.  
 
 
 Wang (GMR) Weissleder (MR) Kopelman (BAM) 
Device Size 8 x 16 x 3 cm 20 x 12 x 5 cm 15 x 15 x 50 cm 
Analysis Time 20 min 30 min 40 min 
Sample Volume 50 μL 5 μL 100 μL 
Magnetic Field Type Electromagnet Permanent (NdFeB) Electromagnet 
Magnetic Field 
Strength 8 mT 500 mT 5 mT 
Magnetic Field 
Frequency 208 Hz 21.3 MHz 50 Hz 
Magnetic Particle 
Size 50 nm 
38 nm 
 1 μm 1 μm 
LOD Buffer 13 fM (Lactoferrin) 57 fM (TNF-α) 1 pM (Tag peptide) 80 fM (Thrombin) 
LOD Serum 4.8 pM (hCG) 5.7 pM (TNF-α)  4.7 pM (VEGF) 7.5 nM (Thrombin) 
Device Material Costs $194 $100 $250 
 
Table 5.2—Comparison of various performance metrics of the Wang GMR system, the 
Weissleder MR system, and our BAM system. Sources of the information are [29, 30] for 
the Wang system and [31-34] for the Weissleder system. 
 
 In terms of magnetic properties, there are some differences between the systems. 
Both the Wang GMR and our system use an electromagnet, while the Weissleder MR 
system uses a NdFeB permanent magnet. The Wang GMR uses a magnetic field of 
amplitude 8 mT driven at 208 Hz, [30] while our system uses a field amplitude of 5 mT 
driven at 50 Hz. The Weissleder MR field is much stronger, with a field strength of 500 
mT driven at 21.3 MHz, [32] however, since it uses a pulsed permanent magnet rather 
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than an electromagnet, its overall size is not much bigger. The Wang GMR system uses 
50 nm iron oxide nanoparticles, [29, 30] while the Weissleder MR field uses both similar 
38 nm iron oxide nanoparticles, as well as larger 1 μm particles. [34] Our system uses the 
same Dynal 1 μm particles that the Weissleder MR system uses.  
 Comparing LODs reported on different analytes is a little bit difficult, because the 
LOD depends on the quality of the affinity molecules used, but for each of the methods 
I’ve included the lowest limits of detection reported. For the Wang GMR, the lowest 
LOD reported in buffer was 13 fM for the antibacterial molecule lactoferrin, and the 
lowest LOD reported in serum was 4.8 pM for the pregnancy hormone human chorionic 
gonadotropin (hCG). [30] The only marker reported in both buffer and serum was the 
inflammatory cytokine TNF-α, which had a buffer LOD of 57 fM and a serum LOD of 
5.7 pM, [30] suggesting that the system loses about two orders of magnitude transitioning 
from buffer to serum. In the Weissleder MR, the lowest reported LOD in buffer was 1 
pM for tag peptide, [33] and the lowest reported LOD in serum was 4.7 pM for the 
angiogenesis factor VEGF. [31] As discussed earlier in this dissertation, the lowest LOD 
found for BAM in buffer is 80 fM for thrombin, and in serum the lowest LOD is 7.5 nM, 
also for thrombin.  
 The final metric to consider is the cost of the device. For the purposes of this 
discussion, I will focus only on the material costs of the device, because the final cost of 
the device will likely have to include substantial research and development and marketing 
outlays, which would significantly increase the total cost. Wang et. al estimate the 
material cost of their device at $194, which includes $105 for the electronic components, 
$40 for the battery, $18 for the metal enclosure, and $31 for the rest of the device 
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assembly. [29] Weissleder et. al provide a rough estimate of $100 for the total cost of 
their device, but do not provide any details on how they arrived at that number. [32] For 
our device, we estimate a total cost of around $250, with $40 for the electromagnetic 
coils, $50 for the amplifier, $100 for the photodiodes, $20 for the laser, and $40 for 
remaining components like electronics and filtering circuits.  
Ultimately, the three devices have a good number of similarities. They are similar 
in size, price, analysis time, and sample volume. The Wang GMR and our system use 
similar magnetic fields and have similar buffer LODs. The Wang GMR and the 
Weissleder MR have similar serum performance, and the use of 40-50 nm particles. 
BAM and the Weissleder MR share the use of the 1 μm magnetic beads. The primary 
difference exists in the Weissleder MR’s use of the much more powerful NdFeB 
permanent magnets and higher buffer LOD (perhaps mitigated by the fact that the device 
was optimized for cell detection rather than protein detection).  
 
Future Work 
For future work on this project, it seems that it might be worthwhile to move 
towards incorporating antibodies that are known to have relatively low affinity for serum 
proteins into BAM, in order to get a better sense of how this method could perform in a 
clinically relevant environment. For example, Chikkaveeraiah et. al have shown two pairs 
of sandwich antibodies, against prostate specific antigen (PSA), a prostate cancer 
biomarker, and interleukin-6 (IL-6), an inflammatory cytokine, that have femtomolar 
level sensitivity in human serum in a magnetic nanoparticle-based electrochemical assay. 
[35] Gnedenko et. al have shown a pair of sandwich antibodies against cardiac myoglobin 
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(cMb), a biomarker for heart attacks, that yield an LOD of 10 pM in human serum when 
used as part of a gold nanoparticle-amplified surface plasmon resonance detection 
system. [36] Jokerst et. al have shown a pair of sandwich antibodies against 
carcinoembryonic antigen (CEA), a cancer biomarker, which yield an LOD of 110 fM in 
human serum when used as part of a quantum-dot sandwich assay detection system. [37] 
Any of these pairs of sandwich antibodies seem like they would be good candidates for 
incorporation into BAM with the goal of showing improved, clinically relevant assay 
performance. The potential future of BAM rests in the ability to perform it in serum with 
clinically relevant antibodies.  
 
Conclusion 
 Unfortunately, attempting to perform BAM in serum with the thrombin aptamers 
ran into a few unexpected complications, including the high affinity of the thrombin 
aptamers for serum proteins and the partial collapse of the PEGylated bead assemblies 
during magnetorotation due to the increased flexibility of the bead linkers. However, 
when comparing BAM to existing thrombin-based diagnostic systems, BAM compares 
quite favorably, both in buffer as well as in serum. BAM also has performance metrics 
similar to the two leading magnetic bead-based diagnostic systems. For future work, 
clinically relevant antibodies should be incorporated into BAM, and a more rigid anti-
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 Over the past few decades, microfluidic devices have garnered much attention as 
potential medical diagnostic tools.  Such devices are particularly attractive for satisfying 
diagnostic needs at the point-of-care or first responder settings without phlebotomy, 
through a high level of automation in a compact device that requires only a droplet of 
sample. [1-4] Advantages of scale and integration with these devices also tend to shorten 
analysis times from hours to minutes, while still achieving quantitative detection of trace 
analytes. The group with which I worked at Sandia has developed an integrated 
microfluidic platform that addresses several requirements for point-of-care diagnostics of 
disease and toxin exposure. [5-10]  To date we have reported on diagnostic assays that 
utilize antibodies as specific recognition elements, as is typical for the majority of 
commercial diagnostics targeting proteins and several other classes of biomarkers.  
However for certain point-of-care settings and first responder scenarios, cost and 
logistical concerns related to stability and shelf-life of antibodies warrant consideration of 
alternative affinity reagents.  Several promising antibody alternatives have been 
developed for therapeutic and diagnostic purposes over the last couple of decades with an 
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emphasis on engineered polypeptide and polynucleotide affinity reagents. [11-13] These 
reagents can be engineered with high affinity, specificity and thermostability, and are 
manufacturable in high purity and reproducibility at low cost once identified.  
Aptamers are selected from randomized nucleotide sequence pools to bind to a 
molecular target (e.g. proteins or peptides) with high affinity and specificity, similar to 
antibodies. [14] Aptamers have been used for a wide range of diagnostic [15-19] and 
therapeutic [20] applications. Most aptamers to date have been derived through the 
SELEX process (systematic evolution of ligands by exponential enrichment), whereby a 
randomly generated pool of oligonucleotides is mixed with the target of interest, and 
oligonucleotides that display affinity for the target are separated and amplified repeatedly 
until the highest affinity oligonucleotides are isolated. [15] Recently, an alternative 
process in which the pool of oligonucleotides is synthesized on beads has emerged which 
reduces the need for multiple enrichment cycles and better accommodates nucleotide 
modifications. The target is mixed with the beads, beads displaying affinity for the target 
are isolated and the corresponding sequences are identified. One or a few rounds of this 
process can yield a sequence with high affinity for the target. [21-26] Incorporating 
modified nucleotides can improve nuclease resistance and enrich chemical complexity of 
the library to enhance affinity and specificity. A prominent example is the thioaptamer, 
incorporating phosphorothioate-modifications in which one (monothio) or both (dithio) 
of the nonbridging oxygen atoms on the phosphate backbone of the nucleic acid strand 
are replaced with sulfur atoms. [24, 26]  
Aptamers exhibit several benefits over antibodies for diagnostic applications. 
Aptamers can be synthesized to target diverse classes of molecules, precisely controlled 
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for desired physicochemical properties, easily modified for purposes such as labeling, 
and produced at low cost with high uniformity from batch to batch.  Aptamers are also 
significantly more robust than antibodies [27], making them better suited for ambient 
reagent storage and point-of-care operation, eliminating cold-chain transportation needs.  
This property is especially advantageous for devices designed for operation in resource-
deficient areas, such as third-world regions and outer space.   
Here, we demonstrate the suitability of nucleic acid affinity reagents in an 
integrated electrophoretic gel-shift detection platform. A model aptamer [28] targeting 
immunoglobulin E (IgE) and a model thioaptamer [29, 30] targeting nuclear factor-kappa 
B (NF-κB) were evaluated.  IgE is one of five classes of antibodies produced by humans, 
and functions primarily in generating allergic reactions [31] and in defending the body 
against parasites. [32]  NF-κB is a protein that controls the transcription of DNA, and 
mediates a wide range of physiological responses, specifically immune responses to 
cytokines and antigens. [33, 34] Improper regulation of NF-κB can lead to a variety of 
diseases, including cancer. [35, 36] 
We investigated assay performance with spiked serum samples where potential 
interference from the serum matrix and high abundance proteins on affinity shift assays 
has been explored to a limited extent with conflicting results.  Some previous 
experiments have reported significant nonspecific interactions between DNA aptamers 
and serum proteins in 10% serum, [37] and in cell culture media, [38] as well as the 
benefits of using an excess of nonspecific aptamers to minimize interactions between 
serum proteins and aptamers in capillary electrophoresis [39] and fluorescence detection. 
[40] Others have reported serum-based aptamer assays without notable interference in 
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capillary electrophoresis [41] and fluorescence polarization anisotropy. [18] Here, a 
competitive inhibition strategy using excess nonspecific oligonucleotides was required to 
suppress serum interference.  
Finally, a distinguishing feature of the integrated platform is the incorporation of 
a size-exclusion membrane to mix and incubate affinity reagents with sample proteins as 
well as to preconcentrate sample proteins and perform sample buffer exchange prior to 
electrophoretic separations analysis. [5, 6, 9]  This mode of mixing reagents automates 
key assay steps on-chip in rapid fashion.  Enhancing the assay sensitivity by several 
orders of magnitude through preconcentration is critical for achieving required detection 
limits for a number of trace analytes. However, the membrane formulations previously 
reported for this platform [6, 42] were optimized for concentrating SDS denatured 
proteins prior to SDS PAGE sizing and for trapping antibody reagents and target proteins 
prior to gel-shift affinity assays.  We report on system performance with aptamer reagents 
of smaller size and higher charge density.  A key benefit of employing aptamers is their 
superior gel shift properties compared to antibodies. Modification and optimization of the 
exclusion membrane were required to improve the performance of integrated aptamer-
based affinity assays.  Best results were achieved through incorporation of a mild charge 
into the nanoporous size exclusion membrane.  We demonstrate that on-chip 
preconcentration, mixing, buffer exchange, and detection of target analytes in serum 
samples are readily achieved within the integrated platform.     
 




Human IgE protein (MW 190,000) was obtained from Scripps Laboratories (San 
Diego, CA). Human Recombinant NF-κB (p50, 50 gsu) was obtained from the Promega 
Corporation (Madison, WI). AlexaFluor 488- and 647-labeled anti-IgE aptamer [28] 
(MW 13,218) was obtained from Integrated DNA Technologies (Coralville, IA).  The 
sequences for these aptamers are shown below: 
5’- AF488-TTTGGGGCACGTTTATCCGTCCCTAGTGGCGTGCCCC – 3’ 
5’- AF647-TTTGGGGCACGTTTATCCGTCCCTAGTGGCGTGCCCC – 3’ 
AlexaFluor 647-labeled anti-NF-κB p50 mouse monoclonal antibody was purchased 
from Santa Cruz Biotechnology (Santa Cruz, CA). AlexaFluor 647-labeled anti-NF-κB 
thioaptamer (MW ~10,188) was obtained from AM Biotechnologies (Houston, TX). Bold 
and underlined bases represent phosphorodithioate modifications. 
5’– AF647-CCAGGAGATTCCAC – 3’ 
3’-       GGTCCTCTAAGGAC - 5’ 
Masking aptamers, (AB77A (MW 17,197) and AB77B (MW 17,268)), synthetic 






3-(trimethoxysilyl)propyl methacrylate (98%), 40% acrylamide, 30% (37.5:1) 
acrylamide/bisacrylamide, bovine serum albumin (BSA), sodium azide, and methyl 
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cellulose powder were purchased from Sigma (St. Louis, MO).  A fraction of BSA was 
labeled with AlexaFluor 647 per the manufacturer’s instructions to be used as an internal 
standard for antibody-based immunoassays.  N,N’-methylenebisacrylamide and 0.2 M pK 
4.6 and pK 6.2 Immobiline solutions were obtained from Fluka (Buchs, Switzerland).  
Water-soluble photoinitiator 2,2’-Azobis[2-methyl-N-(2-hydroxyethyl)propionamide] 
(VA-086) was purchased from Wako Chemicals (Richmond, VA).  10x Tris-Glycine (25 
mM Tris, 192 mM Glycine, pH 8.3) electrophoresis buffer was purchased from BioRad 
(Hercules, CA). Deionized water (18.2 MΩ) was obtained using an Ultrapure water 
system from Millipore (Milford, MA).  Off the clot mouse serum was purchased from 
Innovative Research (Novi, MI).  Upon receipt, serum was thawed at 37°C, mixed with 
0.05% (w/v) sodium azide, filtered with 0.2µm syringe filters (Whatman, UK), aliquotted 
and stored at -20°C until use. 
 
Microchip Fabrication 
Glass (fused silica) microchips were designed in-house and fabricated by Caliper 
Life Sciences (Hopkinton, MA) using standard photolithography, wet etching, bonding 
and dicing methods.  Two previously-described microchip designs [5, 7]  were used in 
this work: a standard offset T design (Figure 6.1a) and a more complex integrated 
preconcentration device (Figure 6.1b).  Note that, unlike previous publications from our 
group, devices in this work used noncrosslinked 1% methyl cellulose (MC) solutions as 
the sieving media versus the in situ photopolymerized polyacrylamide used previously. 
[6, 42]  1% MC was found to be advantageous for the present application in terms of 
device yield and reusability, while providing sufficient sieving power for the analytes. 
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For both devices, the channel walls were first coated with acrylate-terminated 
self-assembled monolayers as previously described. [6, 8, 42] Briefly, the channels were 
conditioned with 1M NaOH, rinsed with deionized water, and dried thoroughly using a 
vacuum. A 2:3:5 (v/v/v) mixture of 3-(trimethoxysilyl) propyl methacrylate, glacial acetic 
acid, and deionized water was loaded into the channels. Devices were incubated with the 
solution for 30 minutes, rinsed with a 3:7 mixture of acetic acid and water, rinsed with 
deionized water, and thoroughly dried with a vacuum.  Next, the channels of the offset T-
chips were coated with a 5% linear acrylamide coating by loading in a solution of 5% 
acrylamide, 0.2% (w/v) VA-086 photoinitiator and exposing to a 100W flood UV lamp 
for 6 minutes.  Following exposure, excess solution was removed via vacuum and the 
channels were flushed twice with MeOH and stored dry until use.   
 
Figure 6.1—Schematics of offset T-chip and preconcentration chip designs. (a) Offset T-
chip: S = Sample Inlet, B = Buffer Inlet, SW = Sample Waste Outlet and BW = Buffer 
Waste Outlet. Approximate length from junction to BW is 2.9 cm. Detector is positioned 
approximately 15 mm from junction.  (b) Preconcentration chip: Ap = Aptamer Inlet, S = 
Sample Inlet, B = Buffer Inlet, LB = Loading Buffer, SW = Sample Waste, BW = Buffer 
Waste Outlet. Detector is positioned approximately 15mm from membrane.  All channels 
are 100µm wide × 35µm deep.  Voltage schemes for conducting assays included in the 




 For the integrated preconcentration devices, the nanoporous polyacrylamide 
membranes were fabricated prior to coating the devices with the 5% linear acrylamide 
coating.  Membrane fabrication was accomplished using in situ photopolymerization 
techniques previously described. [5, 6, 9]  Briefly, the devices were loaded with a 
solution of acrylamide monomer, bisacrylamide crosslinker, and VA-086 photoinitiator.  
For neutral size-exclusion membranes, this solution composed 45%T, 12%C (where %T 
represents the total monomer mass concentration, and %C represents the mass percentage 
of crosslinker to total monomer).  For charged membranes, this solution composed 
40%T, 12%C, 18.4 mM pK 4.6 Immobiline, and 1.6 mM pK 6.2 Immobiline (solution 
pH = 4.4).  ~ 50-µm-wide membranes were defined in the channel by exposure to a 
shaped UV laser beam (355nm frequency-tripled Nd:YAG).  Following membrane 
polymerization, excess monomer solution was removed via vacuum, channels were 
rinsed twice with MeOH and filled with 5% linear acrylamide solution for coating, as 
was done with the offset T chips.  Following the photopolymerized coating, the chips 
were rinsed with MeOH, dried via vacuum, and stored dry until use. 
 
Microchip Operation 
1% MC solution was prepared by slowly dissolving 1.5 g of methyl cellulose in 
100 mL 1X Tris-Glycine buffer over a hot plate.  The solution was then immediately 
chilled and stirred in an ice bath until all MC was dissolved.  Prior to use, the chips were 
filled with the 1% MC gel solution via capillary wicking.  Previous work has 
demonstrated excellent resolution between free aptamer and complex peaks through 
capillary electrophoresis or capillary zone electrophoresis modes without the use of a 
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sieving matrix. [16, 43] However, we employ the 1% MC liquid gel here because (a) our 
assays are being developed for a multiplexed chip using a single matrix that must resolve 
some species that require sieving, and (b) we have found sieving gels more compatible 
with integrated preconcentration using nanoporous size-exclusion membrane.  Chips 
were loaded into custom manifolds, as previously described. [10].  Buffer solution (no 
MC) is continually flowed by gravity through the channels composing the backside of the 
nanoporous membrane in the integrated preconcentration chips to help negate any ion 
depletion effects on either side of the membrane.  Samples (fluorescently-labeled aptamer 
+ target analyte) were mixed in 1% MC gel solutions and added to the sample reservoir 
on the manifold following a 10 minute incubation at room temperature.  For the 
preconcentration experiments, the aptamer and target analyte were diluted in separate 
solutions and loaded into corresponding reservoirs on the manifold.  During all 
experiments, the total sample volume was held constant at 80 μL. In each sample, the 
concentration of aptamer was fixed at 10 nM, and the concentration of spiked target 
varied from 0.250-80 nM for IgE and 2-80 nM for NF-κB. Soaking the manifold in a 5 
mg/mL solution of BSA between runs reduced sample adsorption to the sides of the 
manifold, and improved signal quality.   
Platinum electrodes were inserted into each fluid reservoir on the chip and 
connected to a programmable high-voltage power supply developed and fabricated in-
house. For the offset T-chips, separation and detection was accomplished using voltage 
schemes consistent with earlier operation. [7] To load the sample into the main separation 
channel, a 300 V/cm electric field potential was applied between the S and SW reservoirs 
for 60 seconds.  The voltage was then switched to electrophoretically separate the sample 
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in the main channel by applying 300 V/cm between the B and BW reservoirs for 120 
seconds.  For the integrated preconcentration chips, samples were first loaded into the 
aptamer or sample (target) reservoir, then electrophoretically driven to the 
preconcentration membrane by applying 10 V/cm between the respective reservoir and 
the SW reservoir for varying time intervals.  Following preconcentration, samples were 
eluted from the membrane into the separation channel by applying 30 V/cm between the 
LB and BW reservoirs for 10 seconds, then separated by applying 300 V/cm between the 
B and BW reservoirs for 120 seconds.  
Sample migration was observed 15 mm down the separation channel using laser-
induced fluorescence (LIF). Excitation light (argon ion laser, 488 nm and 647 nm) was 
frequency modulated using a mechanical chopper (220-Hz modulation) and reflected off 
a dichroic mirror (XF2010) through a 40x microscope objective (New Focus, Inc., San 
Jose, CA) that defined the detection point on the microchip. Fluorescence was detected 
by a Hamamatsu H5784 photomultiplier tube (PMT). The signal from the PMT was 
demodulated using a lock-in amplifier (Stanford Research Systems, Sunnyvale, CA), and 
the signal was collected using a computer via a data acquisition interface (6020E 
DAQPad, National Instruments, Austin, TX). Data were collected using an in-house 
program written in LabVIEW (National Instruments). 
 
Quantifying Performance 
 Electropherogram peak areas were calculated using a program written in-house. 
Complex (aptamer + target) peak areas are reported as normalized complex peak area 
(complex peak area / [complex peak area + free aptamer peak area]). Dose-response 
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curves were generated by measuring the respective peak areas for varying concentrations 










  +  
     
 (6.1) 
where a is the estimated response at zero concentration of the target, b is the Hill 
coefficient, which refers to the steepness of the sigmoidal dose-response curve and is 
related to the binding constant, c is the mid-range concentration (C50), d is the estimated 
response at infinite concentration, x is the target concentration and y is the normalized 
complex peak area.  Although a reference standard is preferred for peak normalization, 
several chosen reference compounds overlapped with either the free aptamer peak or the 
complex peak. Instead, total fluorescence of the sample was used to normalize 
electropherograms which was deemed adequate for the goals of this study.  
 
Results and Discussion 
Aptamer Performance in Buffer Conditions 
Representative aptamer affinity gel-shift assay results for the anti-NF-κB 
thioaptamer  and the anti-IgE aptamer are presented in Figures 6.2 and 6.3, respectively, 
for a range of target analyte concentrations.  The free aptamer peaks are readily baseline 
resolved from the aptamer-target complex peaks using 1% MC gel solution.   The peak at 
20 seconds corresponds to the free aptamer, while the peak at 60-80 seconds corresponds 
to the aptamer bound to its target. A typical dose-dependent response was observed, with 
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the free aptamer peak decreasing and the complex peak increasing with higher target 
analyte concentrations. 
 The dose responses plotted in Figure 6.2b and Figure 6.3b were fit using the four-
parameter logistic model in equation 6.1. For Figure 6.2b, a = 0.00, b = 1.44, c = 13.11, 
and d = 1.00. For Figure 6.3b, a = 0.00, b = 1.37, c = 3.02, and d = 1.00. The anti-IgE 
aptamer demonstrated dynamic sensitivity over the IgE concentration range of ~0.5-20 
nM, while the anti-NF-κB thioaptamer demonstrated dynamic sensitivity over the NF-κB 
range of ~5-80 nM. These results are consistent with high affinity interactions expected 
for these previously characterized reagents. 
 
 
Figure 6.21—(a) Electropherogram of 10 nM AF647-anti-NF-κB thioaptamer with NF-
κB spiked in buffer conditions.  The peak at 20 seconds is the free aptamer peak (Ap*), 
and the peak around 60 seconds is the aptamer-target complex peak (Ap*-NF-κB). As the 
concentration of target is increased (with constant aptamer concentration), the free 
aptamer peak decreases while the complex peak increases. (b) Dose-response curve of 
AF647-anti-NF-κB thioaptamer with NF-κB spiked in buffer. Curve was fit using the 





Figure 6.3—(a) Electropherogram of 10 nM AF488-anti-IgE aptamer with IgE spiked in 
buffer conditions.  The peak at 20 seconds is the free aptamer peak, and the peak around 
60 seconds is the aptamer-target complex peak. As the concentration of target is 
increased (with constant aptamer concentration), the free aptamer peak decreases while 
the complex peak increases. Peak areas were normalized here by dividing by the total 
fluorescent intensity. (b) Dose-response curve of AF488-anti-IgE aptamer with IgE 
spiked in buffer. Curve was fit using the four-parameter logistic model in equation 6.1; r2 
= 0.955. 
 
To demonstrate potential advantages of aptamers over antibodies for on-chip 
electrophoretic gel-shift detection, we compared the performance of the anti-NF-κB 
thioaptamer with that of an AlexaFluor 647-labeled anti-NF-κB monoclonal antibody.  
Free probes are separated from target-bound affinity probes based on differing 
electrophoretic mobilities, which are a function of the mass to charge ratio of the two 
species. When considering the molecular weight (MW) range of typical assay targets, 
MWtarget ~ 1-200 kDa, the shift in MW upon binding in a direct assay format for aptamers 
(MWaptamer ~ 10 kDa + MWtarget) is much greater than for standard IgG antibodies (MWAb 
~ 150 kDa + MWtarget) due to the smaller size of aptamers. Furthermore, the modest net 
charge density of most biochemical targets compared to the high charge density of 
aptamers favors enhanced mobility shifts upon binding.  Gel shifts are more likely to be 
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resolved with aptamer reagents, particularly for lower molecular weight targets including 
typical cytokines. The immunoassay format was first attempted using the same 1% MC 
gel solution used for aptamer assays, however the sieving power of the liquid gel was not 
sufficient to resolve the free antibody and complex peaks.  A crosslinked polyacrylamide 
gel 8%T, 2.6%C was therefore used to increase sieving power and achieve an 
immunoassay gel-shift.  Electropherograms obtained with an offset T-chip are included in 
Figure 6.4.  The free antibody peak requires much longer elution time at 132 seconds 
compared to the 20 seconds resolution of free aptamer peaks. More importantly, the free 
antibody peak and the immunocomplex peak overlap significantly, preventing 
quantitative analysis of the electropherograms, whereas the aptamer complex is easily 
baseline resolved.  
Although the resolution advantage of aptamers over antibodies is clearly apparent 
for this case by visual inspection of the electropherograms, we can also quantify the 













where T1 and T2 represent the elution time of the free probe and probe-target complex, 
respectively, and τ1 and τ2 represent the standard deviation due to dispersion of the 
respective peaks.  In general, Rs > 1 is desired, while Rs = 1.5 is considered baseline 




Figure 6.4—On-chip detection of NF-κB using a fluorescently-labeled antibody. Peaks 
are normalized to the AF647-labeled BSA (10 nM) standard peak. (a) 10 nM AF647-
labeled anti-NF-κB antibody and (b) 10 nM AF647-labeled anti-NF-κB antibody with 10 
nM NF-κB.  BSA reference standard eluted at ~50 seconds. The second peak represents 
(a) free antibody and (b) free antibody plus antibody-NF-κB complex. In the latter case, 
the antibody-NF-κB complex peak overlaps with free antibody, preventing quantification. 
This example illustrates potential challenges and limitations in separation resolution with 
gel-shift immunoassays.  Targets in this MW range are generally resolved by 
immunoelectrophoresis, but separation conditions may require more extensive 
optimization than aptamers and/or screening of antibody reagents for suitable 
electrophoretic gel-shift properties. 
 
For the antibody-based electropherogram in Figure 6.4, Rs = 0.385 (well below 
desired resolution).  For the corresponding electropherogram of 10nM anti-NF-κB 
thioaptamer and 10nM NF-κB in Figure 6.2a, Rs = 4.86 (well above baseline resolution).  
The resolution of a gel-shift assay is dependent on several factors including the affinity 
probe properties and buffer characteristics and further development would likely yield an 
acceptable immunoassay for a target in this size range.  However, this example highlights 





Aptamer Performance in Serum 
 Running the aptamer-based affinity assays in serum presents a series of additional 
challenges due to sample complexity. Serum contains highly abundant proteins, most 
prominently immunoglobulin and albumin, in addition to high salt concentrations 
compared to optimal electrophoretic separation buffers.  Consistent with some, but not 
all, earlier reported work with aptamer assays in serum, initial electrophoretic evaluations 
here showed significant nonspecific interactions of serum components with the aptamer. 
Figure 6.5a illustrates challenges imposed by non-specific interference, where serum 
concentrations as low as 5% still caused significant loss of the free aptamer peak and 
introduction of multiple non-specific complex peaks.  In attempts to identify interfering 
serum components, the AF647-anti-NF-κB thioaptamer was incubated with an isolated 
mixture of the two most abundant serum proteins, mouse IgG and albumin at 
approximate serum concentrations.  However, no evidence of aptamer interactions with 
these proteins was observed (data not shown). To address non-specific serum interference 
with aptamers, we evaluated a panel of additives  spiked in the sample and running gel 
buffer, including 5 mg/mL of Tween-20, 0.1% (w/v) SDS, 10 mM Triton X-100, a high-
salt buffer, [43]  and excesses of a 10-bp ssDNA ladder and a 100 kDa E. coli plasmid.  
However, none of these initial treatments succeeded in preventing nonspecific serum-
aptamer interactions without also interfering with aptamer-target binding (not shown).  
We therefore evaluated closer analogues of the anti-NF-κB thioaptamer in a 
competitive suppression strategy.  Best success was realized using a 20-fold excess (1.2 
μM) of two thioaptamer candidates similar in size and chemical properties to the anti-NF-
κB thioaptamer but enriched in selection for other targets.  The mixture of these masking 
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aptamers eliminated losses of AF647-anti-NF-κB thioaptamer and the formation of non-
specific complex peaks in 10% serum (Figure 6.5b).   Success using a similar strategy 
with a 40-fold excess of a nonspecific oligonucleotide was previously reported. [39, 40]  
In our experiments, the closer analogues of the anti-NF-κB thioaptamer competed more 
effectively for non-specific binding sites than small ssDNA ladder and larger plasmid 
DNA. Furthermore, this particular masking aptamer mixture was more effective than 
other masking aptamers evaluated and either masking aptamer alone (not shown).  
Importantly, the masking aptamers did not interfere with high affinity binding 
interactions of the AF647-anti-NF-κB thioaptamer with NF-κB.  These results expand 
upon previously-described suppression strategies to mitigate matrix interference and 
emphasize the value in screening close analogues to aptamers under evaluation.  
In contrast to the results observed in simple buffer (Figure 6.2), binding of 
AF647-anti-NF-κB thioaptamer to NF-κB in the presence of 10% serum (including the 
masking aptamers) resulted in two prominent complex peaks.  The first complex peak 
decreased with increasing NF-κB concentration, while the second peak increased.  
Formation of higher order complexes, possibly involving one or more serum components, 
may explain shifts to later elution times at higher NF-κB concentrations. Further 
investigation is needed to elucidate this finding.  A dose-response curve was 
approximated based on the assumption that the second and third peaks both represent 
aptamer-NF-κB complex (Figure 6.6).  Although masking aptamers significantly reduced 
serum matrix interference, the dose-response was shifted by a factor of ~10 limiting 





Figure 6.5—Comparison of assay response in serum with and without addition of a 
competitive suppressing agent.  (a) Electropherograms of 60 nM AF647-anti-NF-κB 
thioaptamer incubated in 5%, 10%, 20% and 50% serum. No NF-κB was added. The 
peak at 20 seconds represents free aptamer. Significant nonspecific serum protein 
interference was observed for all serum percentages in the form of multiple peaks at later 
timepoints.  (b) Electropherograms of 60 nM AF647-anti-NF-κB thioaptamer with 1.2 
μM of the masking aptamers suppressing non-specific interactions in 10% serum spiked 
with 0, 30, 60, 120 and 240 nM NF-κB. The free aptamer peak at 20 seconds decreases 
with increasing serum concentration, as expected. Total area of complex peaks at 40 and 
60 seconds increased with higher NF-κB concentration. The ratio of complex at 40 vs. 60 
seconds decreased with increasing analyte concentration, possibly associated with NF-κB 
dimerization or interaction with one or more serum components.  The dose-response 






Figure 6.6—Dose response curve for the AF647-anti-NF-κB thioaptamer with NF-κB 
spiked in buffer (from Figure 6.2b, closed circles, r2 = 0.981) and in 10% serum (open 
circles, r2 = 0.891).  
 
Preconcentration of Aptamers using a Charged Nanoporous Membrane 
 In previous work [5, 6], the Sandia group has demonstrated the use of nanoporous 
polyacrylamide preconcentration membranes to improve the dynamic range and limit of 
detection of on-chip immunoassays by several orders of magnitude. [9]  However, the 
small size of the aptamers used in this study is comparable to the MW cutoff (~ 10 kDa) 
of membranes utilized for protein preconcentration.  We observed that the aptamer could 
be concentrated at neutral polyacrylamide membranes, but a measurable fraction of the 
aptamer tends to penetrate the membrane under even very mild electric field strengths (< 
10 V/cm).  This results in poor aptamer elution during injection to the separation channel. 
Aptamer penetration into a neutral membrane and losses during injection are shown in 
fluorescence micrographs (Figure 6.7a). Instead of a clean injection into the separation 
channel, a fraction of the concentrated aptamer plug is retained and slowly leaches from 
the membrane, leading to a smearing of the peak that limits separation resolution and 
quantitative analysis.   
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Hlushkou et al [45] developed a thorough theoretical model of electrokinetic 
enrichment across a charged membrane.  They show that the ion-permselectivity of a 
charged membrane leads to enhanced concentration polarization of ions across the 
membrane, thereby disrupting the analyte transport near the membrane.  Immobilizing 
negatively charged constituents within preconcentration membranes has previously been 
shown to impact exclusion of small analytes and we have also found this to be true in 
earlier evaluations of membrane recipes for integrated electrophoretic applications 
involving both DNA and proteins. However, recipes have not previously been optimized 
to facilitate efficient transfer of electrophoretically concentrated analyte into the 
separation channel without peak distortion.  In fact, surface immobilized charge within 
such membranes is known to induce concentration polarization that interferes with 
several aspects of preconcentration [6, 45] and also subsequent transfer to a separation 
channel. [6] Our optimization strategy was based on formulating a high percentage 
polymer with a modest degree of immobilized charge to exclude DNA while minimizing 
the polarization expected with a highly acidic membrane. Another concern was whether 
low solution pH in the immediate vicinity of the membrane may interfere with 
aptamer/protein binding.   
To control membrane acidity, dilute concentrations of acrylamido buffering 
compounds (Immobilines) were added to the membrane monomer formulation (18.4 mM 
pK 4.6 Immobiline, 1.6 mM pK 6.2 Immobiline, total solution pH = 4.4).  Experimental 
observation under an epi-fluorescent microscope (Figure 6.7b) revealed that the aptamer 
stacked against the negatively- charged membrane without translocating across the 
membrane boundary and cleanly released into the separation channel with no smearing.  
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To quantify the improvement in preconcentration efficiency with the pH 4.4 membrane in 
an integrated format, 10 nM AF647-anti-NF-κB thioaptamer in 1% MC was 
preconcentrated in chips containing both a charged and a neutral membrane. The 
efficiency of the pH 4.4 membrane was close to optimal based on linear increases of 
AF647-anti-NF-κB thioaptamer peak areas with respect to preconcentration time (Figure 
6.7c) in contrast to an apparent plateau in preconcentration levels at higher 
preconcentration times with the neutral membrane.  (Note that the peak areas in this 
figure are normalized by the peak area following 30 seconds of preconcentration, 
whereas complex peak areas in the other figures in this chapter were normalized by the 
total fluorescence in the electropherogram.)  Also critical for integrated preconcentration 
and separations based analysis is that the mildly charged membrane did not adversely 
impact reproducibility, peak shapes, elution times or the linearity of enrichment with 
respect to preconcentration time.  No concentration polarization effects were noted with 
the pH 4.4 membrane under the electric fields used in this work, perhaps due to the 
continually-flowing buffer solution on the backside of the membrane.  However, 
concentration polarization may be of issue under higher fields or longer preconcentration 
times. At further extremes of pH, a highly acidic membrane incorporating acrylic acid 
groups exhibited several symptoms associated with concentration polarization including 
i) significant drops in current with similar applied electric fields, ii) diffuse collection of 
labeled aptamer near the membrane during loading or preconcentration, iii) significant 
smearing of aptamer during injection into the separation channel, and iv) high run to run 




Figure 6.7—Comparison of neutral vs. charged (pH 4.4) preconcentration membrane 
performance.  AF647-anti-NF-κB thioaptamer aptamer loaded to membrane under 10 
V/cm for varying preconcentration times.  (a) Micrographs of loading and injection of 
aptamer at neutral membrane.  A portion of the preconcentrated aptamer plug penetrates 
the neutral membrane and slowly elutes during injection, causing smearing of the injected 
plug.  (b) Micrographs of loading and injection of aptamer at charged membrane.  
Compare clean release in (b) with that in (a).  (c) Plot of aptamer peak area following 
preconcentration at charged (filled circles) vs. neutral (open circles) membranes.  Data is 
normalized by the 30 second preconcentration peak area.  The charged membrane 
produces a linear concentration rate (r2 = 0.995), while the neutral membrane results in a 
plateau in peak area with increasing preconcentration time (r2 = 0.862).  Error bars 
indicate standard deviations calculated from 3 separate runs.   
 
Integrated Mixing, Preconcentration, Incubation, and Separation 
A fully-integrated affinity assay combining on-chip preconcentration, mixing, 
incubation, and separation was demonstrated using this device incorporating membranes 
optimized for aptamer exclusion (Figure 6.8).  Aptamers proved to be viable as affinity 
reagents for all steps of the integrated workflow.   Fluorescent aptamer was rapidly and 
efficiently mixed with target sample loaded electrophoretically from separate reservoirs; 
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representative electropherograms are shown in Figure 6.8a. Although sample 
concentration of NF-κB was fixed at 20 nM, decreases in free AF647-anti-NF-κB 
thioaptamer peak area and corresponding increases complex peak areas were achieved by 
increasing preconcentration times.  Normalized complex peak areas increased 
sigmoidally with preconcentration times as shown in Figure 6.8b, indicating efficient 
preconcentration, mixing and binding.  Incubating reagents at the pH 4.4 membrane did 
not inhibit complexation of aptamer and target protein.  This may occur with more acidic 
membranes and/or preconcentration conditions inducing significant concentration 
polarization, but this possibility was not further explored. 
 
 
Figure 6.8—Integrated preconcentration and mixing of NF-κB with AF647-anti NF-κB 
thioaptamer at a charged nanoporous membrane.  (a) Electropherograms obtained 
following 30 second preconcentration of 10nM AF647-anti-NF-κB thioaptamer, followed 
by 0 to 180 second preconcentration of 20nM NF-κB, and a 60 second buffer 
incubation/wash.  (b) The data from part (a) plotted as normalized complex peak area vs. 
NF-κB preconcentration time.  The normalized complex peak area increases sigmoidally 
with increasing preconcentration time, illustrating the utility of membrane 
preconcentration in improving the sensitivity of the detector.  Error bars indicate standard 





 Aptamers are advantageous for gel shift-based lab-on-a-chip applications in point-
of-care settings due to their robustness, engineered specificity, stability at a wide 
temperature range, and superior gel shift properties. This chapter demonstrates successful 
use of aptamers in an integrated on-chip platform where sample can be preconcentrated, 
mixed with aptamer and injected into a separation channel for quantitative gel-shift 
analysis. To achieve quantitative assay results in serum, we also demonstrated significant 
mitigation of nonspecific interference effects between the thioaptamer and serum 
components by adding an excess of nonspecific oligonucleotides to the sample and 
running gel solutions.   
 This work also presents a basis for optimizing preconcentration membranes to 
effectively exclude and preconcentrate aptamers without inducing concentration 
polarization and without localized pH extremes that might interfere with integrated 
separations analysis.  Adding modest amounts of acrylamido buffering components into 
the polymer matrix to impart a slight negative charge in the membrane enabled successful 
binding assays following highly efficient preconcentration of aptamer via both size and 
charge.  
Aptamers were first synthesized twenty years ago, and are still developing as 
diagnostic agents.  We anticipate continued progress in aptamer design and synthesis and 
further incorporation of aptamers into commercial systems due to the inherent benefits of 
aptamers over conventional antibodies.  Combined with the high sensitivity, small 
analyte consumption, low power requirements, and ease of use of our device, this 
technology can rapidly provide clinically relevant results in challenging resource-limited 
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environments — a vast improvement over many current models. The use of aptamers in 
integrated on-chip electrophoretic molecular recognition assays provides a powerful new 
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Summary and Future Directions 
 
Summary 
 This dissertation has demonstrated the ability to use the magnetorotation of 
superparamagnetic microbeads as a signal transduction method for measuring the 
concentration of a protein in solution. Two main versions of the method were shown: 
Label-Acquired Magnetorotation (LAM), where the attachment of 1 μm 
superparamagnetic beads to 10 μm mother spheres was mediated by the target protein; 
and Bead Assembly Magnetorotation (BAM), where the gravity- and magnetism-driven 
formation of 1 μm superparamagnetic bead assemblies in an inverted droplet was 
mediated by the target protein. BAM was shown to be the more sensitive of the two 
methods, with a limit of detection (LOD) of 80 fM, versus 300 pM for LAM. The LOD 
for BAM is one of the lowest LODs ever reported for the thrombin-aptamer pair; in a 
survey of twenty other signal transduction methods reported for the thrombin-aptamer 
pair, this LOD was lower than all but one, which is significantly more complex and time 
consuming. 
 Chapter 2 described the initial development of LAM, and demonstrated its proof-
of-principle by using biotin-coated particles as the analyte mimics and streptavidin as the 
affinity molecule mimic. Mother spheres could acquire rotation with as few as two 
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daughter beads attached to them, and the rotational frequency of mother spheres 
increased linearly with the number of attached daughter beads. This chapter introduced 
the concept of using magnetic beads as analyte labels, attaching them to a larger sphere, 
and then achieving rotating of the resulting complex. The rotation of a mother sphere was 
shown to be stable for over sixty minutes. This chapter demonstrated the feasibility of 
magnetorotation as a signal transduction mechanism. 
 Chapter 3 expanded on the initial development of LAM, in chapter 2, 
demonstrating the performance of LAM with a real protein and affinity molecule pair, 
thrombin and its aptamers. This was the first time that magnetorotation was shown to 
work as a signal transduction mechanism for the detection of a protein. The LOD for this 
experiment was 300 pM, although computer simulations indicated that there was 
potential for improvement within this system.  
 Chapter 4 described the development of BAM, the second iteration of LAM. This 
method of bead assembly proved to be much more sensitive than its predecessor, with an 
LOD of 80 fM, i.e. over three orders of magnitude better than LAM. The reproducibility 
of BAM was also much better than LAM. In addition to magnetorotation, fractal analysis 
of images of the bead clusters proved to be an effective signal transduction mechanism. A 
simple laser-and-photodiode system proved to be an effective set-up for the detection of 
magnetorotation without the use of a microscope, as a possible prototype for a portable 
detection system.  
 Chapter 5 highlighted the challenges faced when trying to transfer the operation 
of a thrombin-based BAM into serum. The nonspecific interactions between the serum 
proteins and the bead surfaces were partially mitigated by functionalizing the bead 
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surfaces with PEG, although nonspecific interactions between the serum proteins and the 
aptamers were still a problem. Additionally, the partial collapse upon rotation of bead 
assemblies that include PEG was an additional unexpected setback. These issues 
combined to result in BAM having an LOD in serum four orders of magnitude lower and 
with worse vertical resolution than in serum. Despite these problems, BAM still had an 
LOD close to the lowest values reported for thrombin aptamers in serum, suggesting that, 
due to the fact that they were initially developed for therapeutic, not diagnostic, 
applications, the thrombin aptamers themselves might be ill suited for use in serum. 
 Chapter 6 demonstrated the use of aptamers as affinity reagents in a capillary 
electrophoresis detection system. The aptamers were shown to be advantageous relative 
to antibodies for capillary electrophoresis detection applications, because their smaller 
molecular weight resulted in better resolution between the free aptamer peak and the 
complex peak. The analyte for these experiments was the nuclear transcription factor NF-
κB. Problems of nonspecific interference from serum components were mitigated by the 
use of excess nonspecific aptamer to compete for serum binding sites. Also, the use of an 




 The most immediate future direction for this project would be the incorporation of 
antibodies against clinically relevant biomarkers. While aptamers have several 
advantages as affinity molecules, they also have two primary disadvantages. The first is 
that while aptamers are very simple and inexpensive to produce, their initial development 
154 
 
is a very labor- and time-intensive process, and due to various intellectual property issues 
surrounding them, very few aptamers are available for clinically relevant analytes. Thus 
the thrombin aptamers used in this dissertation, as well as by the many comparison 
papers, were not optimized for avoiding non-specific interference from serum molecules. 
The second is that because they are naturally produced in the bloodstream, antibodies 
tend to be better at avoiding nonspecific serum interactions. Some possible clinically 
relevant sandwich antibody-analyte pairs that could be incorporated into BAM include 
PSA, CEA, CA125, cMb, and Hsp72.  
However, there are several issues that are significant for considering the future of 
this technology. The first is the collapse of the PEG-functionalized assemblies used to 
mitigate the nonspecific binding of serum to the beads, under the effects of the rotating 
magnetic field. PEG is the primary surface coating molecule that is used to protect micro- 
and nano-scale surfaces from biofouling from molecules such as serum proteins. Its 
unsuitability for BAM necessitates identifying additional candidate molecules that could 
be used to allow for the performance of BAM in serum.  
 The second, and perhaps more critical issue to be addressed, in terms of long-term 
clinical applicability of this technology, is the landscape of competing technologies. 
Within the field of magnetic particle-based diagnostics, work in magnetic relaxation 
(MR) from the Weissleder group and work in giant magnetoresistance (GMR) from the 
Wang group represent extremely formidable competitors. They have achieved 
femtomolar-level detection, in serum, using clinically-relevant antibodies, in rapid, 
compact, portable formats. While it is certainly possible that, with additional 
improvements to BAM, it could reach comparable LODs, it seems unlikely that it could 
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surpass them. Those two techniques have been under development for a much longer 
period of time, and with a much greater amount of resources at their disposal, compared 
to the BAM technique; they are simply further along in their development. Additionally, 
the low femtomolar range is the floor of clinically-relevant concentrations of most 
biomarkers, so even if a more sensitive device could be developed, its application would 
be limited to only a few special cases.  
 In conclusion, this dissertation has demonstrated the development of bead 
assembly magnetorotation as a signal transduction mechanism, performed with either 
rotational period analysis or with fractal image analysis, with a portable laser-and-
photodiode detection setup, giving a very low LOD for thrombin in buffer, and includes a 





Performance of BAM in Larger Hanging Droplets 
 
 The BAM experiments discussed in Chapters 4 and 5 all featured 1 μL inverted 
droplets placed in the 1.5 mm wells on Teflon-coated glass slides. However, we believe 
that the LOD could be significantly decreased by using larger droplets. There is a 
minimum number of beads in solution (about 500) needed to create an assembly large 
enough to produce a useful signal, and, as shown in Table 4.1, the number of thrombin 
molecules per bead at the limit of detection is relatively constant. Therefore, there is an 
absolute minimum number of thrombin molecules (roughly 500 beads x 150 thrombin 
molecules/bead = 75,000 molecules) in a droplet necessary for a detection event to occur. 
Since, for a given thrombin concentration, the number of thrombin molecules per droplet 
increases linearly with the volume of the droplet, we would expect that the LOD would 
decrease with inverse linear proportionality to the volume of the droplet, so that, for 
example, if we were able to perform BAM in a 10 μL droplet, we would expect to see a 
10-fold decrease in the LOD.  
 We attempted to create larger droplets that would be stable enough to perform 
BAM, but, unfortunately, these attempts were not successful. The primary challenge in 
creating and using the larger droplets was the appearance of convection currents that 
were persistent in the droplet, which disrupted the formation of the bead assemblies. The 
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currents could be seen by the movement of beads in the droplet. These currents occurred 
in droplets ranging from as small as 2 μL to as large as 50 μL.  
 
Experimental 
 Several strategies were explored to mitigate the effects of the currents on the 
droplets by stabilizing them. We attempted to immerse the droplets in silicone oil, but a 
combination of the gravity and the hydrophobic nature of both the aptamers and the 
native bead surface resulted in the beads breaking through the oil-water interface. We 
attempted to place a biologically inert cellulose dialysis membrane at the oil-water 
interface, but the beads stuck to the membrane. As a final strategy we attempted to add 
glycerol to the droplets to increase their viscosity and stabilize them. We examined four 
different droplet sizes, 2.3 μL, 4.6 μL, 8.0 μl and 12.7 μL, which were formed on Teflon-
coated glass slides of four different sizes, 2 mm, 2.5 mm, 3 mm, and 3.5 mm. The 
volumes were chosen so as to keep to same droplet shape factor as was present in the 
original experiments. Four different glycerol concentrations were examined, 0.01%, 
0.1%, 1% and 10%, in the same thrombin binding buffer as discussed in chapters 3, 4 and 
5. A glycerol-free buffer solution was used as a control. The droplets were prepared 
according to the procedure given in the Materials and Methods section of Chapter 4. A 






Results and Discussion 
 Figure A.1 shows a series of images of the droplets formed in glycerol solutions. 
Based on these images, it appears that the glycerol solutions were not effective in 
mitigating the convection currents in the droplets. Although there does not appear to be a 
specific pattern in the types of currents that form, the currents seem to be more 
pronounced in the 8.0 μL and 12.7 μL droplets. The 12.7 μL droplets with 10%, 1% and 
0.1% glycerol appear to show cases where the currents have the most pronounced effects. 
In all cases, the convection currents prevented the beads from forming stable assemblies 
at the bottom of the droplets. 
It appears that in order to attempt to perform BAM in larger droplets, a strategy to 
mitigate the presence of convection currents in these droplets would need to be 
developed. Immersing the droplets in oil, with or without a membrane, prevents the 
formation of assemblies, and the addition of glycerol to the solutions does not appear to 
prevent convection currents from disrupting the formation of bead assemblies at the 









































     
Figure A.1—A collection of images from four different droplet sizes (2.3 μL, 4.6 μL, 8.0 
μL and 12.7 μL), with five different glycerol concentrations (0.01%, 0.1% 1% and 10%, 
plus glycerol-free buffer control), illustrating the presence of convection currents in the 
larger droplets. The bead assemblies should be in a tightly-packed circular arrangement. 
As the bead assemblies move under the influence of the convection currents, they tend to 




Calculation of Nearest-Neighbor Bead Angles and Assembly Radius of Gyration as 
Potential Signal Transduction Methods 
 
 In Chapter 4, we showed three different signal transduction methods for BAM: 
magnetorotation, fractal dimension, and lacunarity. While these three methods worked 
well, we wanted to explore whether there might be additional methods by which we 
could measure a property of the bead assembly that would correlate well with the 
thrombin concentration. We chose to examine two potential methods: calculating the 
angle between each bead in the assembly and its adjacent neighbors, and calculating the 
angle of gyration of the assembly as a whole.  
 
Experimental 
 The work here was performed with a computer analysis of previously collected 
experimental data. The experimental data used here is the 22 μg/mL bead concentration 
(all thrombin concentrations) dataset from Chapter 4 that was used for the fractal 
dimension and lacunarity calculations. The images used were collected at 20x and 40x 
magnifications. The computer program used to perform the calculations and analysis here 
was written in MATLAB, and is included in Appendix C-3.  
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 The first step in performing this analysis was to write a program that would 
identify the position of each bead within the projected image; once the coordinates of 
each bead were identified, further analysis could be performed. To identify the center of 
each bead, we took advantage of the fact that, in the 2-dimensional projected images, due 
to the way the bead scatters light, the center of each bead was brighter than its edges. For 
each pixel, which will be referred to here as “pixel zero,” its intensity was compared to 
that of its eight adjacent neighbors (including diagonals). If the intensity of the pixel zero 
was greater than 7 of its 8 neighbors, it was passed on to the second stage of analysis. In 
the second stage, the 16 pixels neighboring the first eight pixels (so the next-nearest 
neighbors from pixel zero) were examined, and if pixel zero had an intensity greater than 
15 out of the 16 next-nearest pixels, then pixel zero  was determined to be the center of 
the bead. As the final test, since each bead had a diameter of approximately 12-14 pixels 
(40x magnification) or 6-7 pixels (20x magnification), for a pixel to be considered the 
center of a bead, there could be no overlapping bead centers with a diameter of 12-14 (or 
6-7) pixels (the exact radius of exclusion was individually tuned to each image, in part 
due to the effects of the curvature of the droplet on creating some three-dimensional 
behavior within the assembly).  
 The nearest-neighbor angle calculations were performed by finding all the beads 
within a distance of 1.1 times (to allow for slight errors in calculating the average center 
of the beads) the average diameter of each bead, and calculating all combinations of 
possible angles between the central bead and the adjacent beads. The angle was 
determined by calculating the distance between the beads, and then applying the law of 
cosines to calculate the angle C, as shown in Eq. B.1 below, where a, b and c are the 
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Based on the results shown in Figure 4.4, since at high protein concentration the 
fractal dimension of the assembly is approximately 1.7, the same as that of a diffusion 
limited aggregate (DLA) [1], our hypothesis was that the angular distribution of the bead 
assembly should be the same as that of a DLA. To test this hypothesis, we created a 
1000-bead DLA simulation with full range of motion (beads not confined to moving in 
discrete steps along a square lattice), for comparison of the angular distribution with the 
experimental data.  
The radius of gyration, Rg, [2] of each assembly was calculated from the formula 
in Equation B.2 below, where rk is the position of each bead and rmean is the center of 
mass of the assembly of N beads. 
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Results and Discussion 
 A series of images of bead assemblies, and the positions of three bead assemblies 
(100 fM, 1 pM and 10 pM at a bead concentration of 22 μg/mL), as determined by the 







Figure B.1—Images of 22 μg/mL bead assemblies (at 40x magnification) at three 
different thrombin concentrations: 100 fM (top), 1 pM (middle) and 10 pM (bottom). 
 
 Based on the program that calculates the position of each bead in the assembly, 
the nearest-neighbor angular distribution for nine assemblies of different thrombin 





















































concentrations, ranging from 100 fM to 46 pM, were calculated and plotted on a 
histogram, as shown in Figure B.2 below. This figure does not show any significant trend 
across the plots, other than perhaps a slight increase in the relative size of the peak at 60 
degrees as the thrombin concentration increases. We had expected to see a peak in the 
distribution at 180 degrees, and decreasingly monotonically to 60 degrees, which is 
clearly not present in these images. However, such a trend could be seen in the DLA 
angle distribution, as shown in Figure B.3 below. 
   
   
   
Figure B.2—A series of histograms showing the distribution of adjacent nearest-
neighbor beads within nine bead assemblies of varying thrombin concentrations at 22 
μg/mL bead concentrations: 100 fM, 216 fM and 464 fM (left to right, top row), 1 pM, 
2.16 pM and 4.64 pM (left to right, middle row), 10 pM, 21.6 pM and 46.4 pM (left to 
right, bottom row). 


























































































































Figure B.3—The result of a 1000 bead DLA simulation (left). The distribution of 
nearest-neighbor bead angles from the 1000 bead DLA simulation (right). 
 
 Additionally, the data in Figure B.3 shows the distribution that we had expected: a 
maximum near 180 degrees, decreasing monotonically down to 60 degrees. This 
distribution is significantly different from those shown in Figure B.2. This suggests that 
our bead assemblies have at least some characteristics that differ from those of DLAs.  
 The radius of gyration of bead assemblies of nine different thrombin 
concentrations, as measured in pixels, were calculated, and are shown in Figure B.4 
below.  
 
Figure B.4—Plot of the average radius of gyration (± SD) of bead assemblies at ten 
different thrombin concentrations (each point represents the average of four 
measurements). 
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 While the plot in Figure B.4 shows the expected trend, an increase in radius of 
gyration with increasing thrombin concentration, there is a lot more error in the data than 
was expected. Compared to the plots for fractal dimension and lacunarity, this data 
appears to be much noisier, and does not appear to fit well to the shape of a logistic 
curve. In conclusion, it appears that, compared to magnetorotation, fractal dimension and 
lacunarity, the nearest-neighbor bead angular distribution and radius of gyration do not 
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MATLAB Computer Codes 
 
C-1 








%1. Copy and paste this file into the same folder as the data 
%2. Make sure the data file is a .txt file 
%3. Enter the file name below where it says M(:,2)=csvread('*.txt'); 
%4. Enter the frame rate (in frames per second) right below that 
%5. Run the program 
%6. Output is rotational frequency in mHz 




%This version modified on 7/21/2010 to turn the iterations into a 
proper 





%FILE INPUT AND PARAMETERS 
%********************************************************** 
%This is where you input the text file with the angles 
M(:,2)=csvread('1.4 amp 1.txt'); 
  
%x is the frame rate (in fps) 
x=50; 
  
%cutoff is the fraction of the standard deviation above the median for 




%threshold is the largest value for delta for which we will try to 
remove 
%points. If the delta does not exceed the threshold, then no more 
points 
%will be removed. The units of the threshold is degrees. The default 
%setting of the threshold is +/- 2%. 
threshold=0.02*360; 
  
%If intermediate is set equal to 1, then the plots of the each 
iteration 
%will be shown. If intermediate is set equal to 0, then the plots of 
each 




%PROCESSING THE RAW DATA 
%************************************************************* 
  
%len is the length of the matrix 
len=length(M); 
  
%x is the frame rate in fps. This line inserts the time stamp for each 
%point based on the frame rate 
M(:,1)=(0:1/x:1/x*(len-1)); 
%N is the new matrix with the zero values removed. The x-values (time) 
are 




   if M(i,2)~=0; 
       N(end+1,:)=M(i,:); 




%This fits a linear line to the values in N. p(1) is the slope of the 
line. 
%p(2) is the y-intercept 
%S contains error information for the polyval function 
[p S]=polyfit(N(:,1),N(:,2),1); 
  
%polyval evaluates the polynomial. p is the polynomial. N(:,1) are the 
%x-values at which we will evaluate the polynomial.  
%y is the the polynomial p evaluated at points N(:,1). This means that 
y is 
%the y-values for the best-fit line of the data.  
%delta is the limit of the confidence region. To plot error bands, plot 









% %plots both the raw data points, and the best fit line. The data 
points are 







axis([0 time 0 500]) 





%original_size is the number of points in the original data set, before 
we 




%ANALYZING THE RESULTS TO REMOVE OUTLIERS THROUGH COOK'S DISTANCE 
%**************************************************************** 
  
%Counter counts the number of iterations the program runs through 
%N is the matrix of values that enters the loop. The points that are 
%preserved are written in the matrix Q. The original N is then erased, 
and 
%Q becomes the new N. Therefore, N and Q are erased and rewritten every 




    counter=counter+1; 
%This is the correct formula for the hat matrix. Confirmed through R. X 
is 
%the matrix of X values 
X=N(:,1); 
hat=X*inv(X.'*X)*X.'; 
% Sigma is the deviation. N(:,2) is the actual data points. y is the 
fitted 
% data points based on a linear regression. This is for 1 degree of 
% freedom. 
sigma=sqrt(sum((N(:,2)-y).^2)/(length(N)-2)); 
%epsilon is the residuals 
epsilon=N(:,2)-y; 
%r_stud is the studentized residuals 
r_stud=epsilon./(sigma*sqrt(1-(diag(hat)))); 
%jack is the jackknife residuals 
jack=r_stud.*sqrt((length(N)-2)./(length(N)-1-r_stud.^2)); 




%For 148 points, and alpha = 0.05, Bonf criteria = -3.67 
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%For 148 points, and alpha = 0.1, Bonf criteria = -3.47 
%subplot(2,4,5), plot(jack,'.') 



















    figure 
    
subplot(1,2,1),plot(N(:,1),N(:,2),'.',N(:,1),y,'k',N(:,1),y+delta,'r',N
(:,1),y-delta,'r') 
    xlabel('Time (sec)') 
    ylabel('Degrees') 
    
subplot(1,2,2),plot(N(:,1),cook,'.',(0:1/x:max(N(:,1))),median(cook)+cu
toff*std(cook),'k--') 
    xlabel('Time (sec)') 
    ylabel('Cooks Distance') 
end  
%Q is the new matrix with the outliers removed 
Q=[]; 
len=length(N); 
%Any points that lie under the cutoff Cook's Distance (mean + 
cutoff*std)    
     
for j=1:len 
    if cook(j)<median(cook)+cutoff*std(cook) 
        Q(end+1,:)=N(j,:); 
    end 
end 
  























%RE-EVALUATING THE ORIGINAL DATA POINTS BASED ON THE FINAL REGRESSION 
%******************************************************************** 
  
%R is a copy of the original data set (with zeros removed) from above 
  
X=R(:,1); 
%This takes the polynomial p, calculated in the last round of the above 



















%The cutoff for the final result is, instead of based on cook's 
distance, 
%based on distance from the best-fit line. The reason I do this, 
instead of 
%using the Cook's Distance, is because I'm no longer evaluating the 
points. 
%I'm simply trying to include all the points that lie on the line, and 
%exclude all those that do not lie on it. 
for j=1:len 
    if R(j,2)>(y(j)-threshold)&&R(j,2)<(y(j)+threshold); 
        Q(end+1,:)=R(j,:); 
    end 
end 
  














axis([0 time 0 500]) 
N=[]; 
N=Q; 
%final_size is the number of points used in the final data set 
final_size=length(Q); 
% %The slope of the line p(1) is in degrees/second. Dividing by 360 
converts 
% %degrees to rotations. Flipping the sign gives Hz. Multiplying by 
1000 
% %gives mHz.  








[freq_mat r_squared counter original_size final_size] 
%csvwrite('data.csv', [name time x cutoff threshold freq_mat r_squared 













Code for Calculating the Expected Dose-Response Curves for Sandwich Complex 
Based on Binding Kinetics 
 
 
% The main program.  Based on the code written by Foad Mashayekhi for 
BE110 
% NMHW3 taught by Dr. Kamei at UCLA. The original files are in the 
BE110 
% folder in the 2011/04/28 Data folder. This uses a fixed step Euler 
method  
% and plots the output.  To run, place  
% example.m, integrator3.m, solver.m, and deriv1.m in your current 
MATLAB 
% directory, then enter "example.m" into the MATLAB command window. 
  
% This program attempts to model the binding kinetics of the two-site 
% "sandwich" assay. There are 6 components: The protein (P), Capture 
% Antibody (Q1), Detection Antibody (Q2), and three complexes (Q1P, 
Q2P, 
% and Q1PQ2). 
  
% There are two primary reactions that take place: 
% Q1 + P <-> Q1P (forward and reverse constants k1 and k2) 
% Q1P + Q2 <-> Q1PQ2 (forward and reverse constants k3 and k4) 
  
% And two secondary reactions that can also take place: 
% Q2 + P <-> Q2P (k5 and k6) 







%MSC =  mother sphere concentration (spheres/uL) 
MSC=1000; 
%MSV = mother sphere volume (uL) 
MSV=40; 
%BC = bead concentration (mg/mL) 
BC=1; 





%To set a single protein concentration value 
% protein=1e-12; 
  












%This runs in two parts, representing the two steps of the sandwich 
assay. 
%This first part only concerns the equation Q1 + P <-> Q1P. After this 
%equation reaches equilibrium, we will assume a complete wash. We will  
%transfer the final concentrations of Q1 and Q1P to the second step, 
and 






D = [Q1_naught 0 protein(a) 0 0 0]; % Sets the initial conditions for 








ti = 0;     % Initial time 
tf = 540;    % Final time     
dt = 1;     % Step size 
tout = 1;   % Time interval at which data points will be recorded 
  
t = ti; % Initializes the time variable 
tp = t; % Stores the time values for output    
Dp = D; % Stores the solution values for output 
  
% The while loop below continues executing the integration routine 
until  
% the independent variable, t, reaches its final value, tf. 
  
while (t < tf) 
    tend = t + tout; 
  
    % This if statement corrects for situations where the interval 
between 
    % ti and tf isn't evenly divisible by the output interval.  
    if (tend > tf) 
        tend = tf; 
    end 
    h = dt; 
     
    % Calls the "integrator3" function, which computes the solution for  
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    % a single output interval defined by "tout". 
    [D,t] = integrator3(D,t,h,tend); 
    tp = [tp ; t];  % Updates the array that stores time values for 
output 








%SET INITIAL CONCENTRATIONS OF Q2 HERE 
D = [Dp(end,1) Q2_naught 0 Dp(end,4) 0 0]; % Sets the initial 








ti = 0;     % Initial time 
tf = 540;    % Final time     
dt = 1;     % Step size 
tout = 1;   % Time interval at which data points will be recorded 
  
t = ti; % Initializes the time variable 
tp = t; % Stores the time values for output    
Dp = D; % Stores the solution values for output 
  
% The while loop below continues executing the integration routine 
until  
% the independent variable, t, reaches its final value, tf. 
  
while (t < tf) 
    tend = t + tout; 
  
    % This if statement corrects for situations where the interval 
between 
    % ti and tf isn't evenly divisible by the output interval.  
    if (tend > tf) 
        tend = tf; 
    end 
    h = dt; 
     
    % Calls the "integrator3" function, which computes the solution for  
    % a single output interval defined by "tout". 
    [D,t] = integrator3(D,t,h,tend); 
    tp = [tp ; t];  % Updates the array that stores time values for 
output 










% This accounts for saturation of the mother spheres, and scales to 
convert 
% binding concentration to rotational frequency, based on a binding 
capacity 
% of the mother spheres of 300 beads.  
for a=1:length(protein) 
    if Comp_conc(a,1)>1.42e-9 
        Comp_conc(a,1)=1.42e-9; 














xlabel('Protein Concentration (M)') 












%Source: Muller, Freitag, et al., J. Thrombosis Hemostasis 6:2105-2112 
  





























function [dnew,tnew,error] = solver(D,t,h) 
   
  
k1 = deriv1(D,t)*h; 
k2 = deriv1(D+1/5*k1,t+1/5*h)*h; 
k3 = deriv1(D+3/40*k1+9/40*k2,t+3/10*h)*h; 















if 0.00001*d5(1) >= abs(d4(1)-d5(1)) 
    error=1; 
else 
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% Computes the solution for the output interval specified by tout. 
  
function [D,t] = integrator3(D,t,h,tend) 
  
while (t < tend) 
     
    % This if statement corrects for situations where the output 
interval 
    % isn't evenly divisible by the step size. 
    if (tend - t < h) 
        h = tend - t; 
    end 
  
    % Calls solver.m to compute a solution value for a given step size, 
    % specified by "h". 
    [Dnew,t,error] = solver(D,t,h); 
  
     
    %This part deals with the error. The solver function checks the 
error 
    %against the given parameters, and returns a value of "1" if the 
error 
    %is too great. If a value of "1" is returned, then the step size is 
    %reduced and is run again 
    if error == 1 
        h=h/2; 
        [Dnew,tnew,error] = solver(D,t,h); 
    end 
     
    D = Dnew; 















%Written by Ariel Hecht, August 17, 2012 
%A = Raw data matrix 
%B = Thresholded data matrix 
%C = Copy of B matrix to be manipulated in the section of the code 
%converting raw x-y intensity values into bead positions 
%D = Positions of Beads Matrix (m x 2 matrix) 
%x = column value (corresponding to x-coordinate of bead) 
%y = row value (corresponding to y-coordinate of bead) 
%MATLAB does row first, column second 
%******************************** 
  
%This version last revised 1/4/13 
  
%INPUT IMAGE FILE 
A = imread('4.64 pM 40x_0_120613-172925', 'bmp'); 
  
%BEAD POSITION OUTPUT FILE NAME 
bead_output='junk.csv'; 
  










%Number of bins in histogram 
bins=36; 
  











%Threshold is intensity of pixels below which a pixel has to be to be 
















%Takes each pixel, and checks the first layer of pixels around it (8 in 
%total), and then checks the second layer of pixels around those (16 in 
%total, so two degrees of neighbors away from the central point). If 
the 
%pixel is brighter than all the beads in the first row of neighbors, 
and all 
%the pixels in the second row of neighbors, then it is considered to be 
the 




    for k=3:width-2; 
        if A(j,k)<upper_threshold&&A(j,k)>lower_threshold; 
            first_layer=[]; 
            first_layer(1)=A(j-1,k-1); 
            first_layer(2)=A(j-1,k); 
            first_layer(3)=A(j-1,k+1); 
            first_layer(4)=A(j,k-1); 
            first_layer(5)=A(j,k+1); 
            first_layer(6)=A(j+1,k-1); 
            first_layer(7)=A(j+1,k); 
            first_layer(8)=A(j+1,k+1); 
            second_layer=[]; 
            second_layer(1)=A(j-2,k-2); 
            second_layer(2)=A(j-2,k-1); 
            second_layer(3)=A(j-2,k); 
            second_layer(4)=A(j-2,k+1); 
            second_layer(5)=A(j-2,k+2); 
            second_layer(6)=A(j-1,k-2); 
            second_layer(7)=A(j-1,k+2); 
            second_layer(8)=A(j,k-2); 
            second_layer(9)=A(j,k+2); 
            second_layer(10)=A(j+1,k-2); 
            second_layer(11)=A(j+1,k+2); 
            second_layer(12)=A(j+2,k-2); 
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            second_layer(13)=A(j+2,k-1); 
            second_layer(14)=A(j+2,k); 
            second_layer(15)=A(j+2,k+1); 
            second_layer(16)=A(j+2,k+2); 
             
            first=sort(first_layer,2,'descend'); 
            second=sort(second_layer,2,'descend'); 
                if A(j,k)>first(1); 
                       if A(j,k)>second(1); 
                            dist_mat=zeros(length(C),1); 
                            for m=1:length(C) 
                                dist_mat(m)=sqrt((C(m,1)-j)^2+(C(m,2)-
k)^2); 
                            end 
                             
                            if min(dist_mat)>bead_size 
                                index=index+1; 
                                C(index,1)=j; 
                                C(index,2)=k; 
                            end 
                       end 
                end 
        end 
    end 
end 
             
  
%The first pass through this algorithm may not necessarily capture all 
of 
%the beads. This part of the program does a second run-through in order 
to 
%capture additional beads that may have failed the first time because 
there 
%may have been one neighboring pixel that was brighter. This run 
through 
%captures beads where in the first or second layer there were a few 
pixels 
%brighter than the central one, and then checks to see the distance 
between 
%beads to make sure that it won't overlap with another bead.  
for j=3:height-2; 
    for k=3:width-2; 
        if A(j,k)<upper_threshold&&A(j,k)>lower_threshold; 
            first_layer=[]; 
            first_layer(1)=A(j-1,k-1); 
            first_layer(2)=A(j-1,k); 
            first_layer(3)=A(j-1,k+1); 
            first_layer(4)=A(j,k-1); 
            first_layer(5)=A(j,k+1); 
            first_layer(6)=A(j+1,k-1); 
            first_layer(7)=A(j+1,k); 
            first_layer(8)=A(j+1,k+1); 
            second_layer=[]; 
            second_layer(1)=A(j-2,k-2); 
            second_layer(2)=A(j-2,k-1); 
            second_layer(3)=A(j-2,k); 
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            second_layer(4)=A(j-2,k+1); 
            second_layer(5)=A(j-2,k+2); 
            second_layer(6)=A(j-1,k-2); 
            second_layer(7)=A(j-1,k+2); 
            second_layer(8)=A(j,k-2); 
            second_layer(9)=A(j,k+2); 
            second_layer(10)=A(j+1,k-2); 
            second_layer(11)=A(j+1,k+2); 
            second_layer(12)=A(j+2,k-2); 
            second_layer(13)=A(j+2,k-1); 
            second_layer(14)=A(j+2,k); 
            second_layer(15)=A(j+2,k+1); 
            second_layer(16)=A(j+2,k+2); 
             
            first=sort(first_layer,2,'descend'); 
            second=sort(second_layer,2,'descend'); 
                if xor(A(j,k)>=first(2),A(j,k)>=second(2))==1 
                    dist_mat=zeros(length(C),1); 
                    for m=1:length(C) 
                        dist_mat(m)=sqrt((C(m,1)-j)^2+(C(m,2)-k)^2); 
                    end 
                     
                    if min(dist_mat)>bead_size 
                        index=index+1; 
                        C(index,1)=j; 
                        C(index,2)=k; 
                    end 
                end 
        end 
    end 
end 
  
D(1:index,1:2)=C(1:index,1:2);        
num_beads=length(D) 
  
% subplot(1,2,1),  
figure 
scatter(D(:,2),size(A,1)-D(:,1),35,'filled') 
title('Position of Bead Centers') 
xlabel('Pixels') 
ylabel('Pixels') 
axis([0 width 0 height]) 
  




























%radius is the bead radius. The actual radius is about 5 for 1 um on 
60x 
%obj, but I increase it by 1 to make sure that all beads are included. 
  
  
%This part of the program sets the radius from each bead center within 
%which a bead would have to be to be considered a neighbor for angle 
%calculation. The radius is 1.5 times the distance of the median of the 
%nearest bead. This way, all neighbors are counted, without counting 
%second-level neighbors.  
master_distance=zeros(length(D),1); 
for j=1:length(D); 
    E=zeros(length(D),1); 
    for k=1:length(D); 
        E(k,1)=sqrt((D(j,1)-D(k,1))^2+(D(j,2)-D(k,2))^2); 
    end 
    F=sort(E); 






    E=zeros(length(D),1); %Matrix E holds the distance between the 
point j and all other points in the data set 
    neighpos=[]; %position of neighbors in array 
    calcbeads=[]; %the x-y coordinates of the beads that will be used 
in the calculations 
     
    %This loop calculates the distance between the point j and all 
other 
    %points in the array 
    for k=1:length(D); 
        E(k,1)=sqrt((D(j,1)-D(k,1))^2+(D(j,2)-D(k,2))^2); 
    end 
     
    %This loop checks to see if each point is within a one-bead radius 
of 
    %the point j, and puts all those that are within the array neighpos 
%     for kk=1:length(E); 
%         if E(kk,1)>radius; 
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%             E(kk,1)=0; 
%         elseif E(kk,1)<radius && E(kk,1)>0;  
%             neighpos(end+1)=kk; 
%         end 
%     end 
     
    for kk=1:length(E); 
        if E(kk,1)<radius && E(kk,1)>0.4*radius;  
            neighpos(end+1)=kk; 
        end 
    end 
     
    %calcbeads is the array into which the point j is placed in the 
first row, 
    %and all other neighboring points are populated into the array 
    calcbeads(1,1)=D(j,1); 
    calcbeads(1,2)=D(j,2); 
    for m=neighpos; 
        calcbeads(end+1,1)=D(m,1); 
        calcbeads(end,2)=D(m,2); 
    end 
     
    %This loop calculates the angle between the point j and all other 
    %points using the distance formula and the law of cosines. the 
angle 
    %values are populated into anglearray, from which the histogram is 
    %generated.  
     
    if length(calcbeads)>=3 
    for n=2:length(calcbeads)-1; 
        for p=n+1:length(calcbeads); 
            dist_a=sqrt((calcbeads(1,1)-
calcbeads(n,1))^2+(calcbeads(1,2)-calcbeads(n,2))^2); 
            dist_b=sqrt((calcbeads(1,1)-
calcbeads(p,1))^2+(calcbeads(1,2)-calcbeads(p,2))^2); 
            dist_c=sqrt((calcbeads(n,1)-
calcbeads(p,1))^2+(calcbeads(n,2)-calcbeads(p,2))^2); 
            angle=acos((dist_a^2+dist_b^2-
dist_c^2)/(2*dist_a*dist_b))*180/pi; 
            anglearray(end+1,1)=angle; 
%             if angle<50; 
%                 [calcbeads(1,1) calcbeads(1,2) calcbeads(n,1) 
calcbeads(n,2) calcbeads(p,1) calcbeads(p,2) angle] 
%             end 
        end 
    end 
    end 




















radius=2.5; %radius of one bead 
number=1000; %number of beads in sim 
dim=500; %dimension of square 
  
bead_centers=[dim/2 dim/2];  
  
for m=2:number 
     
    %Determining the starting position of the new bead. Each bead 
starts in 
    %one of the four corners 
    x_start=round(rand); 
    y_start=round(rand); 
    m_pos=[dim*x_start dim*y_start]; 
     
    %Initializes a bunch of variables for the loop. 
    %Collision=0 means there have been no collisions 
    %Collision=1 means that there has been a collision 
     
    collision=0; 
    collision_coordinates=[]; 
    moves=0; 
    reseeds=0; 
     
    while collision==0 
         
        D=size(bead_centers); 
         
        %The movement is on the range [-1 1] 
        x_move=-1+2*rand; 
        y_move=-1+2*rand; 
         
        %Moves the bead based on the random movement 
        m_pos(1)=m_pos(1)+x_move; 
        m_pos(2)=m_pos(2)+y_move;                 
         
        %Checks to see if the bead has moved out of the grid, and if it 
        %has, moves it back into the grid 
        if m_pos(1)>dim || m_pos(1)<0 
            m_pos(1)=m_pos(1)-2*x_move; 
            reseeds=reseeds+1; 
        end 
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        if m_pos(2)>dim || m_pos(2)<0 
            m_pos(2)=m_pos(2)-2*y_move; 
            reseeds=reseeds+1; 
        end 
         
        %Checks to see if a collision has occured; if it has, the whole 
        %while loop terminates 
        for n=1:D(1) 
            if 2*radius >= sqrt((m_pos(1)-
bead_centers(n,1))^2+(m_pos(2)-bead_centers(n,2))^2) 
                collision=1; 
            end 
        end 
    end 
         
    %Once a collision has occured, this moves the bead back along the 
    %direction of its final movement, by 1% of the final movement 
length, 
    %before the collision, until it is no 
    %longer colliding with another bead 
    while collision==1; 
        x_adj=0.01*x_move; 
        y_adj=0.01*y_move; 
        m_pos(1)=m_pos(1)-x_adj; 
        m_pos(2)=m_pos(2)-y_adj; 
        collision=0; 
        for n=1:D(1) 
            if 2*radius >= sqrt((m_pos(1)-
bead_centers(n,1))^2+(m_pos(2)-bead_centers(n,2))^2) 
                collision=1; 
            end 
        end 
    end 
         
    %The final position of the bead is recorded in the bead_centers 
array, 
    %which is the master array for the function 
    bead_centers(end+1,1)=m_pos(1); 
    bead_centers(end,2)=m_pos(2); 
                 
end 
  
% creates a plot of bead positions. circle is a user-defined function 
that 
% must be copied into the same directory as the dla_beads function 
for z=1:length(bead_centers) 
    hold on 





end    
     
